

Supporting Information © Wiley-VCH 2013

69451 Weinheim, Germany

Desymmetrization of *meso-2*,5-Diallylpyrrolidinyl Ureas through Asymmetric Palladium-Catalyzed Carboamination: Stereocontrolled Synthesis of Bicyclic Ureas**

Nicholas R. Babij and John P. Wolfe*

anie_201302720_sm_miscellaneous_information.pdf

Supporting Information

Experimental procedures and characterization data for new compounds in Tables 1–2, Schemes 2–3, and Equation 1.

Table of Contents	
General Considerations	S1
Preparation and Characterization of meso-N-Aryl-2,5-Diallylpyrrolidine-1-Carboxamide	
Substrates	S2
Preparation and Characterization of Bicyclic Urea Products	S7
Deprotection of Bicyclic Urea Product 8c	S22
Conversion of Bicyclic Urea Product 8c to Tricyclic Guanidine 12	S23
Conversion of Bicyclic Urea Product 8c to 9- <i>epi</i> -Batzelladine K 16	S25
Assignment of Stereochemistry	S28
References	S34
Copies of NMR Spectra and HPLC traces	S35

General: All reactions were carried out under a nitrogen atmosphere in flame-dried glassware unless otherwise noted. Tris(dibenzylidene)acetone dipalladium, tri(2-furyl)phosphine, and (*S*)-Siphos-PE were purchased from Strem Chemical Co. and used without purification. Tricyclohexylphosphonium tetrafluoroborate was purchased from Acros Chemical Co. and used without further purification. 2-Di-*tert*-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-triisopropyl-1,1'-biphenyl was purchased from Sigma-Aldrich and used without further purification. All other reagents were obtained from commercial sources and were used as obtained unless otherwise noted. NaOtBu and CuCl were stored in the glove box and removed prior to use. BF₃OEt₂ and POCl₃ were purified by distillation under N₂ prior to use. (*Z*)-1-bromobutene^[1] was prepared according to a slight modification of a literature procedure; the preparation was conducted at rt instead of using microwave heating. (*Z*)-1-bromohexene,^[2] and (*E*)-1-bromohexene^[2] were prepared according to published procedures. Toluene, THF, diethyl ether and dichloromethane

were purified using a GlassContour solvent purification system. Yields refer to isolated yields of compounds estimated to be \geq 95% pure as determined by ¹H NMR analysis unless otherwise noted. The yields reported in the supporting information describe the result of a single experiment, whereas yields reported in Tables 1–2, Scheme 2, and Equation 1 are average yields of two or more experiments. Thus, the yields reported in the supporting information may differ from those shown in Tables 1–2, Scheme 2, and Equation 1. Structural and stereochemical assignments were made on the basis of 2-D COSY, and NOESY experiments. Ratios of diastereomers were determined by ¹H NMR analysis. The reported optical rotation values refer to measurements taken of the isolated mixtures of diastereomers upon which chemical yields were based. Ratios of enantiomers were determined by HPLC analysis. Although diastereomers were not easily separable by chromatography, for most examples (with the exception of **8i** and **8j**) it was possible to separate small amounts of the pure (>20:1 dr) major diastereomer for chiral HPLC analysis.

Preparation and Characterization of *meso-N-*AryI-2,5-Diallylpyrrolidine-1-Carboxamide Substrates

HN^{_Boc}

(±)-*tert*-Butyl octa-1,7-dien-4-ylcarbamate (S1). The title compound was prepared by modifying a procedure published by Veenstra.^[3] A flame-dried flask was cooled under a stream of N₂, charged with dichloromethane (60 mL) and cooled to 0 $^{\circ}$ C. Pent-4-enal (2.96 mL, 30 mmol), allyltrimethylsilane (4.77 mL, 30 mmol) and *tert*-butyl carbamate (3.5 g, 30 mmol) were added to the flask and the resulting solution was stirred for 15 min at 0 $^{\circ}$ C. Distilled BF₃OEt₂ (2.3 mL, 18 mmol) was added and the reaction mixture was stirred for 30 min at 0 $^{\circ}$ C. The mixture was gradually warmed to rt and stirred for 30 min. The reaction was then quenched with saturated aqueous NaHCO₃ (20 mL) and stirred for 5 min at rt. The mixture was transferred to a separatory funnel and the layers were separated. The organic layer was washed with saturated aqueous NaHCO₃ (20 mL) and then the combined aqueous layers were extracted with dichloromethane (15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 3.8 g (56%) of the title compound as a clear colorless oil. This compound was found to exist as a mixture of rotamers as judged by ¹H and ¹³C NMR analysis; data are for the mixture. ¹H NMR (500 MHz, CDCl₃) δ 5.84–5.73 (m, 2 H), 5.10–4.95

(m, 4 H), 4.33 (d, br, J = 7.5 Hz, 1 H), 3.66 (d, br, J = 4.5 Hz, 1 H), 2.26–2.07 (m, 4 H), 1.60– 1.55 (m, 1 H), 1.48–1.40 (m, 1 H), 1.43 (s, 9 H); ¹³C NMR (175 MHz, CDCl₃) δ 155.5, 138.0, 134.4, 117.7, 114.9, 79.0, 49.6, 39.5, 33.9, 30.2, 28.4; IR (film) 3337,1684 cm⁻¹. MS (ESI) 248.1621 (248.1621 calcd for C₁₃H₂₃NO₂, M + Na⁺).



(±)-(E,2R*,5S*)-tert-Butyl 2-allyl-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxylate (S2). A flame-dried Schlenk flask was cooled under a stream of N₂ and charged with Pd₂(dba)₃ (81 mg, 0.089 mmol), tri(2-furyl)phosphine (82 mg, 0.36 mmol) and NaOtBu (853 mg, 8.9 mmol). The flask was purged with N₂, then a solution of **S1** (1.0 g, 4.4 mmol) in freshly distilled xylenes (22.2 mL) was added via syringe and the resulting mixture was stirred at rt for 5 min. (E)-(2bromovinyl)trimethylsilane (1.36 mL, 8.9 mmol) was added and the flask was heated to 137 °C and stirred overnight (ca. 14 h). The mixture was cooled to room temperature and saturated aqueous NH₄Cl (10 mL) and ethyl acetate (10 mL) were added. The layers were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (20 mL). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 1.11 g (77%) of the title compound as a dark red-brown oil. This compound was found to exist as a mixture of rotamers as judged by ¹H and ¹³C NMR analysis; data are for the mixture. ¹H NMR (500 MHz, CDCl₃) δ 5.98–5.92 (m, 1 H), 5.78–5.70 (m, 1 H), 5.68 (d, *J* = 18.5 Hz, 1 H), 5.06-5.01 (m, 2 H), 3.92-3.68 (m, 2 H), 2.64-2.41 (m, 2 H), 2.34 (dt, J = 8.0, 13.0 Hz, 1 H), 2.09 (dt, J = 8.0, 13.0 Hz, 1 H), 1.87–1.82 (m, 2 H), 1.68–1.64 (m, 2 H), 1.46 (s, 9 H), 0.03 (s, 9 H); ¹³C NMR (125 MHz, CDCl₃) δ 154.7, 143.2, 135.4, 132.9, 116.8, 79.0, 58.0, 57.9, 42.1, 42.0, 40.0, 39.8, 28.5, -1.2; IR (film) 1692 cm⁻¹. MS (ESI) 346.2174 (346.2173 calcd for C₁₈H₃₃NO₂Si, M + Na⁺).

General Procedure for Synthesis of *meso-N-Aryl-2,5-Diallylpyrrolidine-1-Carboxamide* Substrates 7. A round-bottom flask equipped with a stirbar was charged with S2 (1.0 equiv) and dichloromethane (0.2 M). Trifluoroacetic acid (1.0 M) was added to the flask and the mixture was heated to reflux and stirred overnight. The solution was cooled to rt, diluted with water, basified with NH₄OH to pH > 12, and transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted with CH_2Cl_2 (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude product was dissolved in dichloromethane (0.2 M) and the appropriate isocyanate (1.1 equiv) was added. The reaction mixture was stirred at rt until starting material had been completely consumed as judged by TLC analysis (ca. 1 h). The crude reaction mixture was concentrated *in vacuo*, and purified by flash chromatography on silica gel.



(2*S*,5*R*)-2,5-Diallyl-*N*-(4-methoxyphenyl)pyrrolidine-1-carboxamide (7a). The title compound was prepared from **S2** (2.13 g, 6.6 mmol) and 4-methoxyphenyl isocyanate (940 µL, 7.3 mmol) in two steps via the general procedure described above. This procedure afforded 1.2 g (61%) of the title compound as a white solid: mp = 63–65 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.25 (d, *J* = 8.4 Hz, 2 H), 6.82 (d, *J* = 9.1 Hz, 2 H), 6.33 (s, 1H), 5.91–5.85 (m, 2 H), 5.20–5.15 (m, 4 H), 3.99–3.96 (m, 2 H), 3.77 (s, 3 H), 2.55 (dt, *J* = 14.0, 7.0 Hz, 2 H), 2.24 (dt, *J* = 7.0, 14.0 Hz, 2 H), 2.02–1.97 (m, 2 H), 1.78–1.74 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 155.5, 155.2, 135.2, 132.3, 121.4, 118.0, 114.1, 58.8, 55.5, 40.2, 29.5; IR (film) 3311, 1635 cm⁻¹. MS (ESI) 301.1917 (301.1911 calcd for C₁₈H₂₄N₂O₂, M + H⁺).



(2*S*,5*R*)-2,5-Diallyl-*N*-(3,4-dimethoxyphenyl)pyrrolidine-1-carboxamide (7b). The title compound was prepared from **S2** (965 mg, 2.98 mmol) and 3,4-dimethoxyphenyl isocyanate (488 μ L, 3.3 mmol) in two steps via the general procedure described above. This procedure afforded 542 mg (55%) of the title compound as a tan solid: mp = 112–114 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.27 (d, *J* = 2.1 Hz, 1 H), 6.77 (d, *J* = 8.4 Hz, 1 H), 6.62 (dd, *J* = 2.8, 8.4 Hz, 1 H), 6.36 (s, 1H), 5.91–5.86 (m, 2 H), 5.21–5.16 (m, 4 H), 4.01–3.97 (m, 2 H), 3.88 (s, 3 H), 3.84 (s, 3 H), 2.57 (dt, *J* = 6.3,13.3 Hz, 2 H), 2.25 (dt, *J* = 7.7, 13.3 Hz, 2 H), 2.03–1.99 (m, 2 H),

1.79–1.75 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 155.1, 149.1, 144.8, 135.2, 133.0, 118.1, 111.4, 110.9, 104.7, 58.7, 56.2, 55.9, 40.2, 29.5; IR (film) 3327, 1635 cm⁻¹. MS (ESI) 331.2018 (331.2016 calcd for C₁₉H₂₆N₂O₃, M + H⁺).



(2*S*,5*R*)-2,5-Diallyl-*N*-(4-chlorophenyl)pyrrolidine-1-carboxamide (7c). The title compound was prepared from **S2** (1.05 g, 3.2 mmol) and 4-chlorophenyl isocyanate (541 mg, 3.5 mmol) in two steps via the general procedure described above. This procedure afforded 574 mg (58%) of the title compound as a white solid: mp = 91–93 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.30 (d, *J* = 9.0 Hz, 2 H), 7.21 (d, *J* = 9.0 Hz, 2 H), 6.51 (s, 1H), 5.91–5.85 (m, 2 H), 5.22–5.16 (m, 4 H), 4.00–3.95 (m, 2 H), 2.55 (dt, *J* = 14.0, 6.5 Hz, 2 H), 2.25 (dt, *J* = 14.0, 7.5 Hz, 2 H), 2.03–1.97 (m, 2 H), 1.79–1.74 (m, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 154.5, 137.9, 135.1, 128.7, 127.4, 120.3, 118.3, 58.9, 40.1, 29.6; IR (film) 3318, 1640 cm⁻¹. MS (ESI) 327.1242 (327.1235 calcd for C₁₇H₂₁ClN₂O, M + Na⁺).



(2*S*,5*R*)-2,5-Diallyl-*N*-(4-bromophenyl)pyrrolidine-1-carboxamide (7d). The title compound was prepared from S2 (1.2 g, 3.7 mmol) and 4-bromophenyl isocyanate (806 mg, 4.1 mmol) in two steps via the general procedure described above. This procedure afforded 827 mg (64%) of the title compound as a off-white solid: mp = 101-104 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.37 (d, J = 7.7 Hz, 2 H), 7.25 (d, J = 7.7 Hz, 2 H), 6.49 (s, 1H), 5.91–5.85 (m, 2 H), 5.21–5.17 (m, 4 H), 3.99–3.97 (m, 2 H), 2.55 (dt, J = 6.3, 14.0 Hz, 2 H), 2.25 (dt, J = 7.0, 14.0 Hz, 2 H), 2.03–1.99 (m, 2 H), 1.80–1.77 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 154.5, 138.4, 135.1, 131.7, 120.7,

118.3, 115.0, 58.9, 40.1, 29.6; IR (film) 3316, 1635 cm⁻¹. MS (ESI) 349.0912 (349.0910 calcd for $C_{17}H_{21}BrN_2O$, M + H⁺).



(2*S*,5*R*)-2,5-Diallyl-*N*-(4-cyanophenyl)pyrrolidine-1-carboxamide (7e). The title compound was prepared from **S2** (1.12 g, 3.46 mmol) and 4-cyanophenyl isocyanate (549 mg, 3.81 mmol) in two steps via the general procedure described above. This procedure afforded 613 mg (60%) of the title compound as a off-white solid: mp = 76–79 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.36 (d, *J* = 7.7 Hz, 2 H), 7.25 (d, *J* = 7.7 Hz, 2 H), 6.49 (s, 1H), 5.92–5.86 (m, 2 H), 5.21–5.17 (m, 4 H), 4.02–3.96 (m, 2 H), 2.55 (dt, *J* = 6.3, 14.0 Hz, 2 H), 2.25 (dt, *J* = 7.0, 14.0 Hz, 2 H), 2.03–1.99 (m, 2 H), 1.80–1.77 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.9, 143.5, 135.0, 133.1, 119.2, 118.6, 118.6, 105.1, 59.1, 39.9, 29.6; IR (film) 3365, 1652 cm⁻¹. MS (ESI) 296.1756 (296.1757 calcd for C₁₈H₂₁N₃O, M + H⁺).



(2*S*,5*R*)-2,5-Diallyl-*N*-(4-nitrophenyl)pyrrolidine-1-carboxamide (7f). The title compound was prepared from **S2** (660 mg, 2.04 mmol) and 4-nitrophenyl isocyanate (368 mg, 2.24 mmol) in two steps via the general procedure described above. This procedure afforded 366 mg (57%) of the title compound as a pale-yellow solid: mp = 96–97 °C. ¹H NMR (700 MHz, CDCl₃) δ 8.15 (d, J = 9.1 Hz, 2 H), 7.50 (d, J = 9.1 Hz, 2 H), 6.93 (s, 1H), 5.94–5.88 (m, 2 H), 5.25–5.21 (m, 4 H), 4.04–4.01 (m, 2 H), 2.56 (dt, J = 7.0, 13.3 Hz, 2 H), 2.29 (dt, J = 7.0, 14.0 Hz, 2 H), 2.07–2.03 (m, 2 H), 1.83–1.79 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.7, 145.5, 142.2, 135.0, 125.1,

118.8, 117.8, 59.2, 39.9, 29.7; IR (film) 3331, 1652 cm⁻¹. MS (ESI) 316.1656 (316.1656 calcd for $C_{17}H_{21}N_3O_3$, M + H⁺).

Preparation and Characterization of Bicyclic Urea Products

General Procedure for Synthesis of Racemic Bicyclic Ureas (for HPLC assays). A flamedried Schlenk tube was cooled under vacuum and charged with the appropriate *meso-N*-aryl-2,5-diallylpyrrolidine-1-carboxamide substrate (1.0 equiv), $Pd_2(dba)_3$ (0.02 equiv), PCy_3 HBF₄ (0.08 equiv), and NaO*t*Bu (1.5 equiv). The flask was evacuated and purged with N₂. Toluene (0.2 M) was added via syringe and the resulting mixture was stirred at rt for 2 min. The appropriate aryl or alkenyl bromide (1.5 equiv) was added and the tube was heated to 100 °C and stirred for 2 h. The mixture was cooled to room temperature and saturated aqueous NH₄CI (5 mL/mmol substrate) and ethyl acetate (5 mL/mmol substrate) were added. The layers were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (5 mL/mmol substrate). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel.

General Procedure for Synthesis of Enantiomerically-Enriched Bicyclic Ureas

A flame-dried Schlenk tube was cooled under vacuum and charged with the appropriate *meso-N*-aryl-2,5-diallylpyrrolidine-1-carboxamide substrate (1.0 equiv), $Pd_2(dba)_3$ (0.02 equiv), (*S*)-Siphos-PE (0.08 equiv), and NaOtBu or NaOMe (1.5 equiv). The flask was evacuated and purged with N₂. Toluene (0.2 M) was added via syringe and the resulting mixture was stirred at rt for 2 min. The appropriate aryl or alkenyl bromide (1.5 equiv) was added and the tube was heated to 100 °C. The solution was stirred for 2 h or until the starting material was completely consumed as judged by TLC analysis. The mixture was cooled to room temperature and saturated aqueous NH₄Cl (5 mL/mmol substrate) and ethyl acetate (5 mL/mmol substrate) were added. 6 M HCl was used instead of NH₄Cl to remove aniline side products if column chromatography could not separate the desired product from aniline side products. The layers were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (5 mL/mmol substrate). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel.



(+)-(Z,3S,4aS,7R)-7-AllyI-2-(4-methoxyphenyI)-3-(pent-2-en-1-yI)hexahydropyrrolo[1,2clpyrimidin-1(2H)-one (8a). The general procedure was employed for the coupling of 7a (60 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 48 mg (68%) of the title compound as a brown oil and as a 7:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]^{23}_{D}$ +9.5 (c 4.3, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.14 (d, J = 8.4 Hz, 2 H), 6.88 (d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.43 (dt, J = 7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.03 (d, J = 17.5 Hz, 1 H), 5.00 (d, J = 9.8 Hz, 1 H), 3.99 (dt, J = 2.1, 9.1 Hz, 1 H), 3.82–3.78 (m, 1 H), 3.79 (s, 3 H), 3.65 (ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 2.80 (dd, J = 5.6, 13.3 Hz, 1 H), 2.29–2.27 (m, 1 H), 2.18– 2.15 (m, 2 H), 2.08 (dt, J = 8.4, 13.3 Hz, 1 H) 1.99–1.88 (m, 4 H), 1.83 (dd, J = 6.3, 12.6 Hz, 1 H) 1.68–1.60 (m, 2 H), 0.89 (t, J = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 157.6, 154.2, 135.8, 135.1, 134.6, 129.3, 124.2, 116.8, 114.1, 58.3, 57.3, 55.4, 52.7, 37.8, 31.3, 31.0, 30.9, 27.8, 20.7, 14.0; IR (film) 1642 cm⁻¹. MS (ESI) 355.2382 (355.2380 calcd for C₂₂H₃₀N₂O₂, M + H^{*}). The enantiopurity was determined to be 86:14 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 2.5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 44.2 and 49.1 min).



(+)-(*Z*,3*S*,4*aS*,7*R*)-7-Allyl-2-(3,4-dimethoxyphenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2*c*]pyrimidin-1(2*H*)-one (8b). The general procedure was employed for the coupling of 7b (66 mg, 0.2 mmol) and (*Z*)-1-bromobut-1-ene (150 μ L, 0.3 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 30 mg (39%) of the title compound as a brown oil and as a 7:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]^{23}{}_{D}$ +7.0 (*c* 2.9, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 6.83 (d, *J* = 8.4 Hz, 1 H), 6.78–6.77 (m, 2 H), 5.77–5.71 (m, 1 H), 5.44 (dt, *J* = 7.0, 10.5 Hz, 1 H) 5.13–5.09 (m, 1 H), 5.03 (d, *J* = 16.8 Hz, 1 H), 5.00 (d, *J* = 10.5 Hz, 1 H), 4.01 (dt, *J* = 2.8, 9.1 Hz, 1 H), 3.86 (s, 6 H), 3.85–3.81 (m, 1 H), 3.66 (ddt, *J* = 2.1, 5.6, 11.2 Hz, 1 H), 2.80 (dd, *J* = 5.6, 12.6 Hz, 1 H), 2.30–2.28 (m, 1 H), 2.18– 2.15 (m, 2 H), 2.07 (dt, *J* = 8.4, 13.3 Hz, 1 H) 2.00–1.96 (m, 1 H), 1.93–1.87 (m, 3 H), 1.83 (dd, *J* = 7.0, 12.6 Hz, 1 H) 1.69–1.63 (m, 2 H), 0.89 (t, *J* = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 154.1, 148.9, 147.2, 135.8, 135.4, 134.7, 124.2, 120.1, 116.8, 112.3, 111.1, 58.5, 57.3, 56.0, 55.9, 52.7, 37.8, 31.3, 31.1, 30.9, 27.7, 20.7, 14.1; IR (film) 1641 cm⁻¹. MS (ESI) 385.2486 (385.2486 calcd for C₂₃H₃₂N₂O₃, M + H⁺). The enantiopurity was determined to be 82:18 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 20.4 and 23.5 min).



(-)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-

c]pyrimidin-1(2*H***)-one (8c).** The general procedure was employed for the coupling of **7c** (305 mg, 1.0 mmol) and (*Z*)-1-bromobut-1-ene (750 µL, 1.5 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd₂dba₃ (18.3 mg, 0.02 mmol), and (*S*)-Siphos-PE (40.4 mg, 0.08 mmol). This procedure afforded 288 mg (80%) of the title compound as a yellow oil: $[\alpha]^{23}_{D}$ –14.3 (*c* 5.3, CH₂Cl₂). ¹H NMR (700 MHz, CDCl₃) δ 7.31 (d, *J* = 8.4 Hz, 2 H), 7.19 (d, *J* = 8.4 Hz, 2 H), 5.77– 5.71 (m, 1 H), 5.45 (dt, *J* = 7.0, 10.5 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, *J* = 16.8 Hz, 1 H), 5.01 (d, *J* = 10.5 Hz, 1 H), 4.01 (dt, *J* = 2.8, 9.1 Hz, 1 H), 3.90 (dt, *J* = 4.2, 10.5 Hz, 1 H), 3.66 (ddt, *J* = 2.1, 4.9, 11.2 Hz, 1 H), 2.78 (dd, *J* = 5.6, 12.6 Hz, 1 H), 2.23–2.15 (m, 3 H), 2.07 (dt, *J* = 9.1, 13.3 Hz, 1 H) 1.99 (dt, *J* = 6.3, 11.2 Hz, 1 H), 1.93–1.88 (m, 3 H), 1.84 (dd, *J* = 6.3, 12.6 Hz, 1 H) 1.69–1.64 (m, 2 H), 0.90 (t, *J* = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.7, 140.8, 135.6, 134.9, 131.2, 129.3, 128.9, 123.8, 117.0, 58.0, 57.4, 52.8, 37.7, 31.3, 31.0, 30.9, 27.8, 20.7, 14.0; IR (film) 1643 cm⁻¹. MS (ESI) 359.1887 (359.1885 calcd for C₂₁H₂₇ClN₂O, M +

H⁺). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 190 nm, RT= 13.4 and 18.1 min).



(-)-(Z,3S,4aS,7R)-7-Allyl-2-(4-bromophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-

clpyrimidin-1(2H)-one (8d). The general procedure was employed for the coupling of 7d (70 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 15 mg (18%) of the title compound as a brown oil and as a 18:1 mixture of diastereomers as determined by ¹H NMR analysis: $\left[\alpha\right]^{23}_{D}$ –21.1 (*c* 0.5, CH₂Cl₂). This material also contained ca. 20% of an unidentified side product. Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.46 (d, J = 8.4 Hz, 2 H), 7.14 (d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.45 (dt, J = 7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, J = 17.5 Hz, 1 H), 5.01 (d, J = 10.5 Hz, 1 H), 4.01 (dt, J = 2.8, 8.4 Hz, 1 H), 3.90 (dt, J = 4.9, 10.5 Hz, 1 H), 3.66 (ddt, J = 2.8, 5.6, 11.2 Hz, 1 H), 2.78 (dd, J = 5.6, 12.6 Hz, 1 H), 2.23–2.15 (m, 3 H), 2.07 (dt, J = 8.4, 13.3 Hz, 1 H) 1.99 (dt, J = 5.6, 11.9 Hz, 1 H), 1.95–1.88 (m, 3 H), 1.84 (dd, J = 6.3, 12.6 Hz, 1 H) 1.69–1.63 (m, 2 H), 0.90 (t, J = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.6, 141.4, 135.6, 134.9, 131.9, 129.7, 123.8, 119.2, 117.0, 57.9, 57.4, 52.7, 37.7, 31.3, 31.0, 30.8, 27.7, 20.7, 14.0; IR (film) 1645 cm⁻¹. MS (ESI) 403.1379 (403.1380 calcd for $C_{21}H_{27}BrN_2O$, M + H⁺). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 14.5 and 20.0 min).



(–)-4-[(Z,3S,4aS,7R)-7-Allyl-1-oxo-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-

2(1H)-yl]benzonitrile (8e). The general procedure was employed for the coupling of 7e (59 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 29 mg (41%) of the title compound as a brown oil and as a 17:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]^{23}_{D}$ –71.0 (*c* 2.9, CH₂Cl₂). This material also contained ca. 5% of 4-aminobenzonitrile. Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.62 (d, J = 9.1 Hz, 2 H), 7.39 (d, J = 9.1 Hz, 2 H), 5.76–5.71 (m, 1 H), 5.45 (dt, J = 7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, J = 16.1 Hz, 1 H), 5.02 (d, J = 9.1 Hz, 1 H), 4.07 (dt, J = 4.9, 10.5 Hz, 1 H), 4.02 (dt, J = 2.1, 8.4, Hz 1 H), 3.68 (ddt, J = 2.1, 5.6, 11.2 Hz, 1 H),2.76 (dd, J = 6.3, 12.6 Hz, 1 H), 2.23 (d, J = 12.6 Hz, 1 H), 2.20–2.14 (m, 2 H), 2.06 (dt, J = 8.4, 13.3 Hz, 1 H), 2.03–2.00 (m, 1 H), 1.97–1.85 (m, 4 H), 1.71–1.63 (m, 2 H), 0.89 (t, J = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.1, 146.6, 135.3, 135.2, 132.6, 127.8, 123.4, 118.9, 117.2, 108.5, 57.7, 57.4, 52.7, 37.4, 31.4, 31.0, 30.8, 27.7, 20.7, 14.0; IR (film) 1648 cm⁻¹. MS (ESI) 350.2227 (350.2227 calcd for $C_{22}H_{27}N_3O$, M + H⁺). The enantiopurity was determined to be 94:6 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 33.2 and 42.9 min).



(-)-(Z,3S,4aS,7R)-7-Allyl-2-(4-nitrophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-

c]pyrimidin-1(2*H*)-one (8f). A modification of the general procedure was employed for the coupling of 7f (63 mg, 0.2 mmol) and (*Z*)-1-bromobut-1-ene (150 μ L, 0.3 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8

mg, 0.016 mmol). In contrast to the general procedure, this reaction was run overnight (16 h) at 120 °C. This procedure afforded 18 mg (24%) of the title compound as a vellow oil and as a 20:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]^{23}_{D}$ –281.3 (c 1.1, CH₂Cl₂). This material also contained ca. 8% of unreacted starting material and ca. 3% of a bicyclic urea side product lacking the butenyl group (tentatively assigned as 7-allyl-3-methyl-2-(4nitrophenyl)-4a,5,6,7-tetrahydropyrrolo[1,2-c]pyrimidin-1(2H)-one). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 8.21 (d, J = 9.1 Hz, 2 H), 7.46 (d, J = 9.1 Hz, 2 H), 5.77– 5.71 (m, 1 H), 5.46 (dt, J = 7.0, 11.2 Hz, 1 H), 5.12 (ddt, J = 2.1, 8.4, 17.5 Hz, 1 H), 5.07–5.03 (m, 2 H), 4.15 (dt, J = 4.,9 9.8 Hz, 1 H), 4.05 (dt, J = 2.8, 9.1 Hz, 1 H), 3.70 (ddt, J = 2.8, 5.6, 11.2 Hz, 1 H), 2.78 (dd, J = 5.6, 13.3 Hz, 1 H), 2.25 (d, J = 13.3 Hz, 1 H), 2.23–2.16 (m, 2 H), 2.10–2.02 (m, 2 H) 1.97–1.87 (m, 4 H), 1.73–1.66 (m, 2 H), 0.90 (t, J = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.0, 148.5, 144.4, 135.3, 135.3, 127.2, 124.1, 123.3, 117.3, 57.8, 57.4, 52.7, 37.3, 31.5, 31.0, 30.8, 27.7, 20.8, 14.0; IR (film) 1649 cm⁻¹. MS (ESI) 370.2126 (370.2125 calcd for $C_{21}H_{27}N_3O_3$, M + H⁺). The enantiopurity was determined to be 96:4 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 1.5 mL/min, λ 310 nm, RT= 19.1 and 26.2 min).



(–)-(*E*,3*S*,4*aS*,7*R*)-7-Allyl-2-(4-chlorophenyl)-3-(hept-2-en-1-yl)hexahydropyrrolo[1,2c]pyrimidin-1(2*H*)-one (8g). The general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and (*E*)-1-bromohex-1-ene (49 mg, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). 6 M HCl was used in the workup to remove 4-chloroaniline side product. This procedure afforded 44 mg (57%) of the title compound as a yellow oil: $[\alpha]^{23}_{D}$ –30.3 (*c* 1.9, CH₂Cl₂). This material also contained ca. 15% of a regioisomeric bicyclic urea product generated from the coupling of 7c and 2-bromohex-1-ene (tentatively assigned as (3*S*,4*aS*,7*R*)-7-allyl-2-(4-chlorophenyl)-3-(2-methylenehexyl)hexahydropyrrolo[1,2-*c*]pyrimidin-1(2*H*)-one). Data are for the major isomer. ¹H NMR (500 MHz, CDCl₃) δ 7.31 (d, *J* = 9.0 Hz, 2 H), 7.17 (d, *J* = 9.0 Hz, 2 H), 5.78–5.70 (m, 1 H), 5.41–5.36 (m, 1 H), 5.17–5.10 (m, 1 H), 5.05–5.00 (m, 2 H), 4.00 (dt, *J* = 2.5, 8.5 Hz, 1 H), 3.92–3.87 (m, 1 H), 3.65 (ddt, *J* = 2.5, 5.5, 11.0 Hz, 1 H), 2.79 (dd, *J* = 6.0, 13.5 Hz, 1 H), 2.28– 2.23 (m, 2 H), 2.10–1.98 (m, 3 H), 1.95–1.87 (m, 3 H), 1.84 (dd, *J* = 6.5, 12.5 Hz, 1 H) 1.69– 1.62 (m, 2 H), 1.29–1.26 (m, 4 H), 0.87 (t, *J* = 7.0 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 153.7, 140.9, 135.6, 134.6, 131.2, 129.4, 128.8, 125.1, 116.9, 57.9, 57.4, 52.6, 37.7, 36.9, 32.2, 31.4, 30.8, 27.8, 22.1, 13.9 (one carbon signal is absent due to incidental equivalence); IR (film) 1643 cm⁻¹. MS (ESI) 387.2207 (387.2198 calcd for C₂₃H₃₁ClN₂O, M + H⁺). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 1.5% IPA/Hexanes, 1.5 mL/min, λ 205 nm, RT= 20.0 and 37.5 min).



(-)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(hept-2-en-1-yl)hexahydropyrrolo[1,2clpyrimidin-1(2H)-one (8h). The general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and (Z)-1-bromohex-1-ene (49 mg, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 6 M HCl was used in the workup to remove 4-chloroaniline side product. This procedure afforded 47 mg (61%) of the title compound as a yellow brown oil: $\left[\alpha\right]^{23}_{D}$ –14.8 (c 3.5, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.31 (d, J = 9.1 Hz, 2 H), 7.19 (d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.45 (dt, J = 7.0, 11.2 Hz, 1 H), 5.15–5.11 (m, 1 H), 5.05–5.00 (m, 2 H), 4.01 (dt, J = 2.8, 8.4 Hz, 1 H), 3.91–3.88 (m, 1 H), 3.66 (ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 2.78 (dd, J = 8.4, 13.3 Hz, 1 H), 2.24–2.14 (m, 3 H), 2.07 (dt, J = 8.4, 14.0 Hz, 1 H), 2.00–1.97 (m, 1 H) 1.95–1.83 (m, 4 H), 1.70–1.62 (m, 2 H), 1.25–1.24 (m, 4 H), 0.86 (t, J = 7.0 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.7, 140.8, 135.6, 133.4, 131.3, 129.4, 128.9, 124.4, 117.0, 58.1, 57.4, 52.8, 37.7, 31.6, 31.3, 31.0, 30.8, 27.8, 27.2, 22.3, 13.9; IR (film) 1642 cm⁻¹. MS (ESI) 387.2203 (387.2198 calcd for $C_{23}H_{31}CIN_2O$, M + H⁺). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 1.5% IPA/Hexanes, 1.5 mL/min, λ 254 nm, RT= 20.9 and 36.2 min).



(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(3-methylbut-2-en-1-yl)hexahydropyrrolo[1,2c]pyrimidin-1(2H)-one (8i). The general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 1-bromo-2-methyl-1-propene (31 µL, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 37 mg (52%) of the title compound as a yellow oil and as a 10:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]_{D}^{23}$ –37.9 (c 2.2, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.30 (d, *J* = 7.7 Hz, 2 H), 7.18 (d, *J* = 9.1 Hz, 2 H), 5.74 (dddd, J = 6.3, 7.7, 10.5, 16.8 Hz, 1 H), 5.04 (dd, J = 2.1, 16.8 Hz, 1 H), 5.01 (d, J = 10.5 Hz, 1 H), 4.89 (dt, J = 1.4, 7.0 Hz, 1 H), 4.00 (dt, J = 2.8, 9.1 Hz, 1 H), 3.88–3.85 (m, 1 H), 3.66 (ddt, J = 2.8, 5.6, 11.2 Hz, 1 H), 2.79 (dd, J = 6.3, 12.6 Hz, 1 H), 2.21–2.16 (m, 2 H), 2.09–2.04 (m, 2 H), 2.02–1.99 (m, 1 H), 1.95–1.89 (m, 1 H), 1.84 (dd, J = 7.0, 12.6 Hz, 1 H) 1.68–1.62 (m, 2 H), 1.64 (s, 3 H), 1.47 (s, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.7, 140.9, 135.6, 134.9, 131.1, 129.3, 128.8, 119.6, 117.0, 58.3, 57.4, 52.8, 37.7, 32.2, 31.1, 30.9, 27.7, 25.7, 17.9; IR (film) 1643 cm⁻¹. MS (ESI) 359.1895 (359.1885 calcd for $C_{21}H_{27}CIN_2O$, M + H⁺). The enantiopurity was determined to be 94:6 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 254 nm, RT= 13.8 and 24.0 min).



(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(2-methylallyl)hexahydropyrrolo[1,2-

c]pyrimidin-1(2*H*)-one (8j). The general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 2-bromopropene (89 μ L, 1.0 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 39 mg

(56%) of the title compound as a yellow oil and as a 20:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]²³_D –33.5 (c 2.9, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.31 (d, *J* = 8.4 Hz, 2 H), 7.19 (d, *J* = 9.1 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.06–5.01 (m, 2 H), 4.79 (s, 1 H), 4.66 (s, 1 H), 4.09–4.06 (m, 1 H), 4.00 (dt, *J* = 2.8, 8.4 Hz, 1 H), 3.66 (ddt, *J* = 2.8, 4.9, 11.2 Hz, 1 H), 2.79 (dd, *J* = 6.3, 12.6 Hz, 1 H), 2.27–2.23 (m, 2 H), 2.12 (dd, *J* = 11.2, 14.0 Hz, 1 H) 2.07 (dt, *J* = 8.4, 13.3 Hz, 1 H), 2.03–1.99 (m, 1 H), 1.95–1.89 (m, 1 H), 1.85 (dd, *J* = 7.0, 12.6 Hz, 1 H) 1.68–1.64 (m, 2 H), 1.55 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 153.7, 141.5, 140.7, 135.6, 131.2, 129.3, 128.9, 117.0, 113.9, 57.5, 55.8, 52.6, 41.8, 37.7, 30.8, 30.5, 27.8, 22.0; IR (film) 1641 cm⁻¹. MS (ESI) 345.1735 (345.1728 calcd for $C_{20}H_{25}CIN_2O$, M + H⁺). The enantiopurity was determined to be 88:12 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 3% IPA/Hexanes, 0.75 mL/min, λ 254 nm, RT= 22.8 and 28.4 min).



(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(4-methylbenzyl)hexahydropyrrolo[1,2-

c]pyrimidin-1(2*H***)-one (8k)**. The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 4-bromotoluene (37 µL, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 66 mg (83%) of the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]^{23}_{D}$ –125.6 (*c* 3.1, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.36 (d, *J* = 8.4 Hz, 2 H), 7.26 (d, *J* = 8.4 Hz, 2 H), 7.06 (d, *J* = 8.4 Hz, 2 H), 6.86 (d, *J* = 7.7 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.04 (d, *J* = 16.8 Hz, 1 H), 5.01 (d, *J* = 10.5 Hz, 1 H), 4.10 (dt, *J* = 4.9 11.2 Hz, 1 H), 4.03 (dt, *J* = 2.8, 8.4, Hz 1 H), 3.76 (ddt, *J* = 2.8, 5.6, 11.2 Hz, 1 H), 2.90 (dd, *J* = 2.8, 13.3 Hz, 1 H), 2.81–2.78 (m, 1 H), 2.53 (dd, *J* = 11.2, 14.0 Hz, 1 H), 2.30 (s, 3 H), 2.09–2.04 (m, 2 H), 2.00 (dt, *J* = 5.6, 11.9 Hz, 1 H), 1.96–1.91 (m, 1 H), 1.85 (dd, *J* = 5.6, 12.6 Hz, 1 H) 1.64–1.59 (m, 1 H), 1.56 (dt, *J* = 6.3, 12.6 Hz, 1 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.6, 140.8, 136.2, 135.6, 134.5, 131.3, 129.3, 129.3, 129.0, 128.9, 117.0, 59.8, 57.5, 52.6, 39.2, 37.6, 30.8, 30.1, 27.8, 21.0; IR (film) 1642 cm⁻¹. MS (ESI) 395.1887 (395.1885 calcd for C₂₄H₂₇CIN₂O, M + H⁺). The enantiopurity was determined to be 92:8 er by

chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 254 nm, RT= 17.3 and 19.4 min).



(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(4-methoxybenzyl)hexahydropyrrolo[1,2clpyrimidin-1(2H)-one (8I). The general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 4-bromoanisole (38 µL, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 58 mg (70%) of the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]_{D}^{23}$ –169.4 (c 2.2, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.35 (d, J = 8.4 Hz, 2 H), 7.25 (d, J = 8.4 Hz, 2 H), 6.89 (d, J = 9.1 Hz, 2 H), 6.79 (d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.04 (d, J = 17.5 Hz, 1 H), 5.01 (d, J = 10.5 Hz, 1 H), 4.08 (dt, J = 4.2, 11.2 Hz, 1 H), 4.03 (dt, J = 2.1, 8.4 Hz, 1 H), 3.77 (s, 3 H), 3.77-3.72 (m, 1 H), 2.87 (dd, J = 3.5. 14.0 Hz, 1 H), 2.80 (dd, J = 6.3, 14.0 Hz, 1 H), 2.51 (dd, J = 11.2, 13.3 Hz, 1 H), 2.09–2.04 (m, 2 H), 2.00 (dt, J = 5.6, 11.9 Hz, 1 H), 1.96–1.91 (m, 1 H), 1.85 (dd, J = 7.0, 12.6 Hz, 1 H) 1.65–1.54 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 158.3, 153.6, 140.8, 135.6, 131.3, 130.0, 129.6, 129.3, 129.0, 117.0, 114.0, 59.9, 57.5, 55.2, 52.6, 38.7, 37.6, 30.8, 30.1, 27.8; IR (film) 1642 cm⁻¹. MS (ESI) 411.1834 (411.1834 calcd for C₂₄H₂₇ClN₂O₂, M + H⁺). The enantiopurity was determined to be 92:8 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 3% IPA/Hexanes, 0.75 mL/min, λ 204 nm, RT= 49.3 and 55.7 min).



(-)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)hexahydropyrrolo[1,2-c]pyrimidin 1(2H)-one (8m). The general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol)

and bromobenzene (32 µL, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 63 mg (83%) of the title compound as a pale brown foam oil and as a 7:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]^{23}_{D}$ –61.2 (*c* 5.6, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.36 (d, *J* = 9.1 Hz, 2 H), 7.27–7.25 (m, 4 H), 7.21–7.20 (m, 1 H), 6.98 (d, *J* = 7.0 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.05–5.00 (m, 2 H), 4.14 (dt, *J* = 4.9, 11.2 Hz, 1 H), 4.03 (dt, *J* = 2.1, 8.4 Hz, 1 H), 3.77 (ddt, *J* = 2.1, 4.9, 11.2 Hz, 1 H), 2.94 (dd, *J* = 3.5, 14.0 Hz, 1 H), 2.80 (dd, *J* = 6.3, 13.3 Hz, 1 H), 2.57 (dd, *J* = 11.2, 14.0 Hz, 1 H), 2.10–2.04 (m, 2 H), 2.03–2.00 (m, 1 H), 1.97–1.91 (m, 1 H), 1.86 (dd, *J* = 6.3, 12.6 Hz, 1 H) 1.66–1.54 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.6, 140.8, 137.6, 135.6, 131.4, 129.3, 129.1, 129.0, 128.6, 126.6, 117.0, 59.7, 57.5, 52.7, 39.6, 37.6, 30.8, 30.2, 27.8; IR (film) 1642 cm⁻¹. MS (ESI) 381.1736 (381.1728 calcd for C₂₃H₂₅CIN₂O, M + H⁺). The enantiopurity was determined to be 90:10 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 21.1 and 24.2 min).



(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-[4-

(trifluoromethyl)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2*H*)-one (8n). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 4-bromobenzotriflouride (42 μ L, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 66 mg (74%) of the title compound as a pale yellow oil and as a 5:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]²³_D – 46.1 (*c* 6.0, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.51 (d, *J* = 7.7 Hz, 2 H), 7.36 (d, *J* = 9.1 Hz, 2 H), 7.24 (d, *J* = 9.1 Hz, 2 H), 7.09 (d, *J* = 7.7 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.05–5.01 (m, 2 H), 4.16 (dt, *J* = 4.2, 11.2 Hz, 1 H), 4.03 (dt, *J* = 2.1, 9.1 Hz, 1 H), 3.76 (ddt, *J* = 2.1, 5.6, 11.9 Hz, 1 H), 3.00 (dd, *J* = 3.5, 14.0 Hz, 1 H), 2.79 (dd, *J* = 5.6, 13.3 Hz, 1 H), 2.66 (dd, *J* = 11.2, 13.3 Hz, 1 H), 2.09–2.00 (m, 3 H), 1.98–1.93 (m, 1 H), 1.87 (dd, *J* = 6.3, 11.9 Hz, 1 H) 1.66–1.56 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.5, 141.7, 140.6, 135.5, 131.6, 129.4, 129.3, 129.2 (q, *J* = 37 Hz), 129.1, 125.6 (q, 3.3 Hz), 124.0 (q, *J* = 270 Hz), 117.1,

59.5, 57.6, 52.6, 39.6, 37.6, 30.8, 30.3, 27.8; IR (film) 1642 cm⁻¹. MS (ESI) 449.1600 (449.1602 calcd for $C_{24}H_{24}CIF_3N_2O$, M + H⁺). The enantiopurity was determined to be 85:15 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 19.9 and 27.5 min).



(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-[4-

(trifluoromethyl)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2*H*)-one (8n). A modified general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 4-bromobenzotriflouride (42 μ L, 0.3 mmol) using NaOMe (16.2 mg, 0.3 mmol) as base and a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 54 mg (60%) of the title compound as a pale yellow oil and as a 10:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]²³_D –51.1 (*c* 2.3, CH₂Cl₂). The enantiopurity was determined to be 90:10 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 19.4 and 26.7 min). Spectroscopic data were identical to those provided above.



(-)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)-3-[4-

(trifluoromethoxy)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2*H*)-one (8o). The general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 1-bromo-4-(trifluoromethoxy)benzene (45 μ L, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 63 mg (68%) of the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as determined by

¹H NMR analysis: $[\alpha]^{23}_{D} -48.7$ (*c* 5.7, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.35 (d, *J* = 9.1 Hz, 2 H), 7.24 (d, *J* = 9.1 Hz, 2 H), 7.10 (d, *J* = 7.7 Hz, 2 H), 6.99 (d, *J* = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.05–5.01 (m, 2 H), 4.13 (dt, *J* = 4.2, 11.2 Hz, 1 H), 4.03 (dt, *J* = 2.8, 8.4 Hz, 1 H), 3.75 (ddt, *J* = 2.8, 4.9, 11.2 Hz, 1 H), 2.93 (dd, *J* = 4.2, 14.0 Hz, 1 H), 2.79 (dd, *J* = 6.3, 13.3 Hz, 1 H), 2.60 (dd, *J* = 10.5, 14.0 Hz, 1 H), 2.10–2.00 (m, 3 H), 1.98–1.92 (m, 1 H), 1.86 (dd, *J* = 6.3, 12.6 Hz, 1 H) 1.67–1.57 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.5, 147.9, 140.7, 136.7, 135.5, 131.5, 130.3, 129.3, 129.1, 121.2, 117.0, 59.6, 57.5, 52.6, 39.1, 37.6, 30.8, 30.3, 27.8 (the CF₃ carbon signal could not be determined due to the appearance of carbon signals from the minor diastereomer in the CF₃ region of the spectrum); IR (film) 1642 cm⁻¹. MS (ESI) 465.1557 (465.1551 calcd for C₂₄H₂₄ClF₃N₂O₂, M + H⁺). The enantiopurity was determined to be 88:12 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 17.1 and 19.8 min).



(-)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)-3-[4-

(trifluoromethoxy)benzyl]hexahydropyrrolo[1,2-*c*]pyrimidin-1(2*H*)-one (8o). A modified general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 1-bromo-4- (trifluoromethoxy)benzene (45 µL, 0.3 mmol) using NaOMe (16.2 mg, 0.3 mmol) as base and a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 48 mg (52%) of the title compound as a pale yellow oil and as an 17:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]^{23}_{D}$ –55.6 (*c* 1.5, CH₂Cl₂). The enantiopurity was determined to be 93:7 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 16.8 and 19.8 min). Spectroscopic data were identical to those provided above.



(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(3-methoxybenzyl)hexahydropyrrolo[1,2-

clpyrimidin-1(2H)-one (8p). The general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 3-bromoanisole (38 µL, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 61 mg (74%) of the title compound as a vellow brown solid and as a 5:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]^{23}_{D}$ –65.1 (c 2.8, CH₂Cl₂). Mp = 132–137 °C. Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.36 (d, J = 8.4 Hz, 2 H), 7.25 (d, J = 9.1 Hz, 2 H), 7.18 (t, J = 8.4 Hz, 1 H), 6.74 (dd, J = 2.1, 8.4 Hz, 1 H), 6.57 (d, J = 7.0 Hz, 1 H), 6.50 (s, 1 H), 5.77–5.71 (m, 1 H), 5.04 (dd, J = 1.4, 16.8 Hz, 1 H), 5.01 (dd, J = 1.4, 9.8 Hz, 1 H), 4.14 (dt, J = 4.2, 11.2 Hz, 1 H), 4.03 (dt, J = 2.1, 8.4 Hz, 1 H), 3.77 (s, 3 H), 3.78–3.73 (m, 1 H), 2.91 (dd, J = 3.5, 13.3 Hz, 1 H), 2.80 (dd, J = 5.6, 13.3 Hz, 1 H), 2.54 (dd, J = 11.2, 14.0 Hz, 1 H), 2.10-2.04 (m, 2 H), 2.03–1.99 (m, 1 H), 1.96–1.91 (m, 1 H), 1.85 (dd, J = 6.3, 12.6 Hz, 1 H), 1.65– 1.56 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 159.7, 153.6, 140.7, 139.2, 135.6, 131.4, 129.6, 129.3, 129.0, 121.4, 117.0, 115.3, 111.3, 59.6, 57.5, 55.2, 52.7, 39.7, 37.6, 30.8, 30.3, 27.8; IR (film) 1642 cm⁻¹. MS (ESI) 411.1841 (411.1834 calcd for $C_{24}H_{27}CIN_2O_2$, M + H⁺). The enantiopurity was determined to be 87:13 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 248 nm, RT= 27.2 and 30.6 min).



(–)-(3*S*,4*aS*,7*R*)-7-Allyl-2-(4-chlorophenyl)-3-(napthalen-2-ylmethyl)hexahydropyrrolo[1,2*c*]pyrimidin-1(2*H*)-one (8q). The general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 2-bromonapthanlene (62 mg, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 66 mg (77%) of the title compound as a white solid and as a 7:1 mixture of diastereomers as determined by ¹H NMR analysis: $[α]^{23}_{D}$ –77.9 (*c* 4.6, CH₂Cl₂). Data are for the major isomer. Mp = 63–65 °C. ¹H NMR (700 MHz, CDCl₃) δ 7.80 (d, *J* = 7.7 Hz, 1 H), 7.75 (t, *J* = 7.7 Hz, 2 H), 7.47–7.44 (m, 3 H), 7.38 (d, *J* = 9.1 Hz, 2 H), 7.31 (d, *J* = 8.4 Hz, 2 H), 7.07 (dd, *J* = 0.7, 8.4 Hz, 1 H), 5.78–5.72 (m, 1 H), 5.04 (d, *J* = 16.8 Hz, 1 H), 5.02 (d, *J* = 9.8 Hz, 1 H), 4.25 (dt, *J* = 4.2, 11.2 Hz, 1 H), 4.06 (dt, *J* = 2.1, 9.8 Hz, 1 H), 3.84 (ddt, *J* = 2.1, 4.9, 11.2 Hz, 1 H), 3.11 (dd, *J* = 3.5, 14.0 Hz, 1 H), 2.81 (dd, *J* = 5.6, 13.3 Hz, 1 H), 2.74 (dd, *J* = 11.9, 14.0, Hz, 1 H), 2.11–2.05 (m, 2 H), 2.04–1.94 (m, 2 H), 1.86 (dd, *J* = 7.0, 12.6 Hz, 1 H), 1.65–1.56 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.6, 140.8, 135.6, 135.1, 133.4, 132.2, 131.4, 130.4, 129.4, 129.1, 128.4, 127.7, 127.3, 127.1, 126.3, 125.7, 117.0, 59.6, 57.5, 52.7, 37.6, 30.8, 31.0, 30.2, 27.8; IR (film) 1646 cm⁻¹. MS (ESI) 431.1886 (431.1885 calcd for C₂₇H₂₇ClN₂O, M + H⁺). The enantiopurity was determined to be 88:12 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 215 nm, RT= 24.4and 28.2 min).



(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(2-methylbenzyl)hexahydropyrrolo[1,2-

c]pyrimidin-1(2*H*)-one (8*r*). The general procedure was employed for the coupling of 7c (61 mg, 0.2 mmol) and 2-bromotoluene (36 µL, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 65 mg (82%) of the title compound as a pale brown oil and as a 5:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]^{23}_{D}$ –30.1 (*c* 5.7, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.36 (d, *J* = 9.1 Hz, 2 H), 7.26 (d, *J* = 8.4 Hz, 2 H), 7.11–7.08 (m, 3 H), 6.93–6.92 (m, 1 H), 5.78–5.71 (m, 1 H), 5.04 (dd, *J* = 1.4, 17.5 Hz, 1 H), 5.01 (dd, *J* = 1.4, 10.5 Hz, 1 H), 4.09 (dt, *J* = 4.2, 12.6 Hz, 1 H), 4.04 (dt, *J* = 2.8, 9.1 Hz, 1 H), 3.86 (ddt, *J* = 2.8, 5.6, 11.2 Hz, 1 H), 2.93 (dd, *J* = 3.5, 14.0 Hz, 1 H), 2.80 (dd, *J* = 5.6, 12.6 Hz, 1 H), 2.62 (dd, *J* = 11.2, 14.0 Hz, 1 H), 2.11–2.02 (m, 3 H), 2.01 (s, 3 H), 1.99–1.94 (m, 1 H), 1.87 (dd, *J* = 6.3, 12.6 Hz, 1 H), 1.65 (ddd, *J* = 6.3, 11.2, 17.5 Hz, 1 H), 1.58 (dt, *J* = 5.6, 12.6 Hz, 1 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.6, 140.7, 136.3, 135.7, 135.6, 131.5, 130.6, 130.3, 129.6, 129.0, 126.8, 126.0, 117.0, 58.4, 57.5, 52.9, 37.7, 36.8, 30.8, 30.1, 27.8, 19.2; IR (film) 1642 cm⁻¹. MS (ESI)

395.1885 (395.1885 calcd for $C_{24}H_{27}CIN_2O$, M + H⁺). The enantiopurity was determined to be 71:29 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 215 nm, RT= 20.1 and 24.3 min).

Deprotection of Bicyclic Urea Product 8c



(-)-(Z,3S,4aS,7R)-N-{4-[7-Allyl-1-oxo-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-2(1H)-yl]phenyl}acetamide (S3). A flame-dried screwtop-flask was cooled under vacuum and charged with Pd₂(dba)₃ (5.2 mg, 0.006 mmol), 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-triisopropyl-1,1'-biphenyl (13.7 mg, 0.03 mmol), K₃PO₄ (182 mg, 0.86 mmol) and acetamide (50.8 mg, 0.86 mmol). The flask was evacuated and backfilled with N_2 , and then a solution of 8c (206 mg, 0.57 mmol) in tert-butanol (3 mL) was added via syringe. The flask was sealed, heated to 110 °C and stirred overnight (14 h). The mixture was cooled to room temperature and the mixture was filtered through a plug of celite, eluted with EtOAc (10 mL), and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to afford 191 mg (88%) of the title compound as a foamy brown solid: mp = 38–42 °C. $[\alpha]^{23}_{D}$ -25.2 (c 5.3, CH₂Cl₂). ¹H NMR (700 MHz, CDCl₃) δ 8.93 (s, 1 H), 7.21 (d, J = 8.4 Hz, 2 H), 6.98 (d, J = 8.4 Hz, 2 H), 5.77–5.72 (m, 1 H), 5.49–5.40 (m, 1 H), 5.07–5.03 (m, 3 H), 4.03 (dt, J =2.8, 9.1 Hz, 1 H), 3.77 (dt, J = 4.2, 10.5 Hz, 1 H), 3.67 (ddt, J = 2.8, 4.9, 8.4 Hz, 1 H), 2.80 (dd, J = 4.9, 12.6 Hz, 1 H), 2.25–2.08 (m, 4 H), 2.05 (s, 3 H) 2.02–1.98 (m, 1 H), 1.95–1.85 (m, 4 H), 1.70–1.64 (m, 2 H), 0.88 (t, J = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 168.8, 154.5, 137.3, 136.6, 135.5, 134.8, 128.3, 124.0, 121.3, 117.1, 58.5, 57.3, 52.8, 37.8, 31.2, 31.0, 30.8, 27.7, 24.0, 20.8, 14.1; IR (film) 3263, 1687, 1624 cm⁻¹. MS (ESI) 382.2493 (382.2489 calcd for $C_{23}H_{31}N_3O_2, M + H^+$).



(-)-(Z,3S,4aS,7R)-7-Allyl-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (9). A Schlenk tube was charged with a stirbar, S3 (39 mg, 0.1 mmol) and CH₃CN (1 mL). A solution of ceric ammonium nitrate (164 mg, 0.3 mmol) in H_2O (1 mL) was added to the reaction flask and the mixture was stirred at rt for 5 min. The mixture was then heated at 50 °C for 15 min before being cooled to rt, at which time EtOAc (5 mL) was added. The mixture was transferred to a separatory funnel and the layers were separated. The organic layer was washed with saturated aqueous Na₂SO₃ (5 mL), saturated aqueous NaHCO₃ (5 mL), and brine (5 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (2% MeOH in CH₂Cl₂) on silica gel to afford 19 mg (77%) of the title compound as a yellow brown solid: $[\alpha]^{23}_{D}$ –63.2 (c 0.5, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ 5.80–5.72 (m, 1 H), 5.57–5.51 (m, 1 H), 5.30–5.25 (m, 1 H), 5.06– 5.02 (m, 2 H), 4.73 (s, 1 H), 4.00 (dt, J = 3.0, 8.5 Hz, 1 H), 3.49 (ddt, J = 3.0, 5.5, 11.5 Hz, 1 H), 3.46-3.41 (m, 1 H), 2.72 (d, J = 14.5 Hz, 1 H), 2.26-2.20 (m, 1 H), 2.13-1.93 (m, 6 H), 1.88-1.77 (m, 2 H), 1.61–1.52 (m, 2 H), 0.96 (t, J = 7.5 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 155.1, 135.6, 135.2, 124.0, 117.0, 56.2, 52.9, 50.0, 38.1, 35.7, 32.3, 30.7, 27.4, 20.8, 14.1; IR (film) 3207, 1652 cm⁻¹. MS (ESI) 249.1963 (249.1961 calcd for C₁₅H₂₄N₂O, M + H⁺).

Conversion of Bicyclic Urea Product 8c to Tricyclic Guanidine 12



(-)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-

c]pyrimidin-1(2*H*)-imine hydrochloride (10). A flame-dried flask was cooled under a stream of N_2 and charged with 8*c* (177 mg, 0.49 mmol) and toluene (5 mL). Freshly distilled POCl₃ (2.5 mL, 27 mmol) was added and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 3 hr). The reaction mixture was cooled to rt and concentrated *in vacuo*. The crude product was dissolved in acetonitrile (5 mL) and a solution of

ammonia (20 mL, 2 M in ethanol) was added. The mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 1 hr). The reaction mixture was concentrated and dissolved in methylene chloride (5 mL). Water (5 mL) was added and the mixture was transferred to a separatory funnel. The layers were separated and the organic layer was washed with saturated aqueous NaCl (3 x 10 mL). The combined aqueous layers were extracted with methylene chloride (3 x 10 mL). The combined organics layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to afford 146 mg (75%) of the title compound as a pale white-yellow foam: $[\alpha]_{D}^{23} - 45.5(c \ 1.1, \ CH_2Cl_2)$. ¹H NMR (700 MHz, CDCl₃) δ 7.48 (d, J = 7.7 Hz, 1 H), 7.40 (d, J = 7.7 Hz, 1 H), 7.29 (d, J = 7.0 Hz, 1 H), 7.14 (d, J = 8.4 Hz, 1 H), 5.96–5.90 (m, 1 H), 5.45 (dt, J = 7.0, 10.5 Hz, 1 H), 5.00–4.93 (m, 4 H), 3.75–3.72 (m, 1 H), 3.62–3.58 (m, 1 H), 2.67 (d, J = 13.3 Hz, 1 H), 2.25 (dd, J = 2.1, 14.0 Hz, 1 H), 2.18–2.16 (m, 1 H) 2.12–2.06 (m, 3 H), 2.03–1.93 (m, 2 H), 1.81–1.68 (m, 4 H), 0.82 (t, J = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 151.3, 136.6, 136.1, 135.8, 134.5, 131.5, 131.4, 130.8, 128.9, 121.7, 118.3, 59.5, 59.1, 53.1, 36.2, 30.8, 30.4, 29.6, 28.1, 20.8, 13.9; IR (film) 3457, 3275, 1636 cm⁻¹. MS (ESI) 358.2048 (358.2045 calcd for $C_{21}H_{29}CIN_3$, M⁺).



(-)-(*Z*,2a*S*,4*S*,7*S*,8a*R*)-5-(4-Chlorophenyl)-7-methyl-4-(pent-2-en-1-yl)-1,2,2a,3,4,5,6,7,8,8adecahydro-2a¹,5,6-triazaacenaphthylen-2a¹-ium chloride (12). A test tube was charged with 10 (39.4 mg, 0.1 mmol), PdCl₂ (3.5 mg, 0.02 mmol), and CuCl (14.8 mg, 0.15 mmol). The tube was capped with a rubber septum, was briefly flushed with oxygen and then an oxygen-filled balloon attached to a needle (via an adaptor) was connected to the tube through the septum. A solution of THF and H₂O (7:1, 1.0 mL) was added to the test tube and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 4 hr). Methanol (1 mL) and NaCNBH₃ (62.8 mg, 1.0 mmol) was added and the mixture was heated to 50 °C until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 3 hr). The reaction mixture was cooled to rt and concentrated *in vacuo*. The crude product was dissolved in methylene chloride (20 mL), the mixture was transferred to a separatory funnel and 2 M HCl (10 mL) was added. The layers were separated and the organic layer was washed with NH₄OH (10 mL) to potentially remove any excess copper. The layers were separated and the organic layer was washed with 2 M HCl (10 mL). The organics layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 31 mg (79%) of the title compound as a pale white-tan oil and as a 5:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]^{23}_{D}$ –38.1 (*c* 0.6, CH₂Cl₂). Data are for the major isomer. ¹H NMR (500 MHz, CDCl₃) δ 7.56 (d, *J* = 7.5 Hz, 2 H), 7.34 (d, *J* = 8.5 Hz, 2 H), 5.57–5.52 (m, 1 H), 5.10–5.05 (m, 1 H), 4.64 (s, 1 H), 3.99–3.90 (m, 2 H), 3.77–3.73 (m, 1 H), 3.69–3.65 (m, 1 H), 2.46–2.32 (m, 5 H), 2.28 (dt, *J* = 3.5, 13.0 Hz, 1 H), 1.99–1.93 (m, 3 H), 1.88–1.80 (m, 2 H), 1.51–1.44 (m, 1 H), 1.22 (d, *J* = 6.5 Hz, 3 H), 0.93 (t, *J* = 7.5 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 148.6, 136.6, 136.5, 135.2, 132.0–129.0 (br, 2 C), 121.9, 59.8, 57.7, 52.1, 47.4, 34.8, 30.0, 29.9, 29.6, 29.4, 20.9, 20.6, 14.0; IR (film) 3276, 1607 cm⁻¹. MS (ESI) 358.2047 (358.2045 calcd for C₂₁H₂₉CIN₃, M ⁺).

Conversion of Bicyclic Urea Product 8c to 9-epi-Batzelladine K 16



(-)-(*Z*,3*S*,4*aS*,7*R*)-*N*-{4-[1-Oxo-7-(2-oxopropyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2*c*]pyrimidin-2(1*H*)-yl]phenyl}acetamide (13). A test tube was charged with *S*3 (300 mg, 0.79 mmol), PdCl₂ (28 mg, 0.16 mmol), and CuCl (117 mg, 1.18 mmol). The tube was capped with a rubber septum, was briefly flushed with oxygen and then an oxygen-filled balloon attached to a needle (via an adaptor) was connected to the tube through the septum. A solution of DMF and H_2O (7:1, 8.0 mL) was added to the test tube and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 4 hr). EtOAc (20 mL) and brine (20 mL) was added and the mixture was transferred to a separatory funnel. The layers were separated and the organic layer was washed with NH₄OH (5 mL) to potentially remove any excess copper. The combined aqueous layers were than extracted with EtOAc (20 mL). The organics layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 230 mg (74%) of the title compound as a pale yellow-pink solid: mp = 68-72 °C. [α]²³_D -38.8 (*c* 0.8, CH₂Cl₂). ¹H NMR (700 MHz, CDCl₃) δ 8.66 (s, 1 H), 7.25 (d, *J* = 8.4 Hz, 2 H), 7.01 (d, *J* = 9.1 Hz, 2 H), 5.44– 5.41 (m, 1 H), 5.06–5.03 (m, 1 H), 4.37–4.34 (m, 1 H), 3.80–3.77 (m, 1 H), 3.66 (ddd, *J* = 2.8, 4.9, 11.2 Hz, 1 H), 3.44 (dd, *J* = 2.8, 9.8 Hz, 1 H), 2.31 (dd, *J* = 9.8, 16.8 Hz, 1 H), 2.26–2.13 (m, 3 H), 2.10 (s, 3 H), 2.06 (s, 3 H), 2.09–2.03 (m, 2 H), 1.91–1.86 (m, 2 H), 1.77 (dd, *J* = 7.0, 13.3 Hz, 1 H), 1.65–1.58 (m, 2 H), 0.88 (t, *J* = 7.0 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 207.5, 168.7, 154.2, 137.2, 136.7, 134.9, 128.3, 123.8, 121.1, 58.5, 53.7, 52.8, 47.6, 31.1, 30.8, 30.2, 29.4, 24.0, 20.8, 14.0 (one carbon signal is absent due to incidental equivalence); IR (film) 3261, 1711, 1687, 1621 cm⁻¹. MS (ESI) 398.2439 (398.2438 calcd for C₂₃H₃₁N₃O₃, M + H⁺).



(-)-(3S,4aS,7R)-7-(2-Oxopropyl)-3-pentylhexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (14). A flame-dried flask was cooled under vacuum and charged with 13 (100 mg, 0.25 mmol) and Pd/C (10 mg). The flask was capped with a rubber septum, was briefly flushed with hydrogen and then a hydrogen-filled balloon attached to a needle (via an adaptor) was connected to the flask through the septum. Methanol (2.5 mL) was added to the flask and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 45 min). The crude product was then filtered through a plug of celite to remove the Pd/C and washed with methanol (5 mL). The crude material was concentrated in vacuo and carried on to the next step without further purification. The crude product was dissolved in CH₃CN (10 mL) and transferred to a round-bottom flask charged with a stirbar. A solution of ceric ammonium nitrate (123 mg, 0.75 mmol) in H₂O (30 mL) was added to the reaction flask and the mixture was stirred at rt for 5 min. The mixture was then heated at 50 °C for 4 hr before being cooled to rt, at which time EtOAc (25 mL) was added. The mixture was transferred to a separatory funnel and the layers were separated. The organic layer was washed with saturated aqueous Na₂SO₃ (15 mL), saturated aqueous NaHCO₃ (15 mL), and brine (15 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to afford 34 mg (51%) of the title compound as a white solid: mp = 84–88 °C. $[\alpha]^{23}_{D}$ –11.7 (c 2.5, CH₂Cl₂). ¹H NMR (700 MHz, CDCl₃) δ 4.79 (s, 1 H), 4.30-4.28 (m, 1 H), 3.48-3.45 (m, 1 H), 3.43-3.39 (m, 2 H), 2.29 (dd, J = 9.8, 16.8 Hz, 1 H),

2.10 (s, 3 H), 2.03–1.98 (m, 2 H), 1.95–1.94 (m, 1 H), 1.72 (dd, J = 7.7, 12.6 Hz, 1 H), 1.54– 1.46 (m, 3 H), 1.38–1.25 (m, 7 H), 0.88 (t, J = 7.0 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 207.7, 155.0, 52.8, 52.8, 50.0, 47.6, 37.8, 32.9, 31.6, 30.6, 30.3, 29.0, 25.5, 22.6, 14.0; IR (film) 3207, 1709, 1649 cm⁻¹. MS (ESI) 267.2065 (267.2067 calcd for C₁₅H₂₆N₂O₂, M + H⁺).



(-)-9-epi-Batzelladine K (16). A flame-dried flask was cooled under vacuum and charged with 14 (25 mg, 0.09 mmol) and dichloromethane (0.9 mL). 2,6-di-tert-butylpyridine (203 µL, 0.94 mmol) and MeOTf (103 µL, 0.94 mmol) were added and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 1 hr). The solvent was then removed in a hood by blowing a constant stream of N₂ over the stirring mixture. The solution was then poured in diethyl ether (20 ml) and washed with 1 M NaOH (10 mL) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was used without further purification. The crude O-methylisourea was dissolved in methanol (2 mL) and transferred to a thick walled glass vial at which time ammonium chloride (10.1mg, 0.19 mmol) was added to this solution. Anhydrous ammonia was bubbled through this solution for ~15 min before the reaction vessel was sealed and heated to 60 °C overnight (14 hr). The reaction was cooled to rt and concentrated in vacuo. The crude guanidine product 15 was used without further purification. Crude product 15 was dissolved in methanol (3 mL), NaCNBH₃ (59 mg, 0.94 mmol) was added and the mixture was heated to 50 ^oC until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 12 hr). The reaction mixture was cooled to rt and concentrated in vacuo. The crude product was dissolved in methylene chloride (20 mL), the mixture was transferred to a separatory funnel and washed with 2 M HCl (2 x 10 mL) and brine (1 x 10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was determined to be a 3:1 mixture of diastereomers by ¹H NMR analysis. The crude material was purified by flash chromatography on silica gel to afford 13 mg (48%) of the title compound as a pale yellow oil. The following data is for the pure isolated major diastereomer. $\left[\alpha\right]_{D}^{23}$ -43.8 (c 0.5, CH₂Cl₂). ¹H NMR (700 MHz, CDCl₃) & 3.80–3.73 (m, 2 H), 3.58–3.53 (m, 1 H), 3.52–3.49 (m, 1 H), 2.26-2.21 (m, 3 H), 2.19 (dd, J = 4.2, 13.3 Hz, 1 H), 1.73-1.64 (m, 2 H), 1.60-1.56 (m, 2 H),2 H), 1.52–1.47 (m, 1 H), 1.44–1.27 (m, 7 H), 1.27 (d, J = 6.3 Hz, 3 H), 0.93 (t, J = 7.0 Hz, 3 H);

¹³C NMR (175 MHz, CDCl₃) δ 149.4, 56.3, 51.6, 48.4, 45.8, 36.2, 35.5, 31.5, 31.2, 30.5, 30.2, 25.5, 22.4, 20.5, 14.0; ¹H NMR (700 MHz, CD₃OD) δ 7.56 (d, *J* = 7.5 Hz, 2 H), 7.34 (d, *J* = 8.5 Hz, 2 H), 5.57–5.52 (m, 1 H), 5.10–5.05 (m, 1 H), 4.64 (s, 1 H), 3.99–3.90 (m, 2 H), 3.77–3.73 (m, 1 H), 3.69–3.65 (m, 1 H), 2.46–2.32 (m, 5 H), 2.28 (dt, *J* = 3.5, 13.0 Hz, 1 H), 1.99–1.93 (m, 3 H), 1.88–1.80 (m, 2 H), 1.51–1.44 (m, 1 H), 1.22 (d, *J* = 6.5 Hz, 3 H), 0.93 (t, *J* = 7.5 Hz, 3 H); ¹³C NMR (175 MHz, CD₃OD) δ 150.4, 57.5, 53.5, 50.2, 47.3, 36.8, 36.1, 32.7, 31.9, 31.3, 30.7, 26.8, 23.6, 20.8 14.3; IR (film) 3284, 3202, 1637 cm⁻¹. MS (ESI) 250.2278 (250.2278 calcd for $C_{15}H_{28}N_3$, M⁺).

Assignment of Stereochemistry

The relative stereochemistry of compound **8k** was assigned on the basis of observed ¹H NMR nOe experiments. Significant nOe relationships are shown below. The stereochemistry of all other bicyclic urea products was assigned based on analogy to **8k**.



The relative stereochemistry of compounds **12** and **16** were assigned on the basis of observed ¹H NMR nOe experiments. Significant nOe relationships are shown below.



The absolute stereochemistry of the urea products was assigned via the synthesis of compound **ent-8c** from pent-4-enal via the route illustrated below in Scheme S1. The optical rotation of product **ent-8c** prepared via this route was opposite that of the product **8c** generated in the Pd-catalyzed carboamination reaction between **7c** and Z-bromobutene. In addition, analysis of

product **ent-8c** by chiral HPLC indicated that **ent-8c** was the enantiomer of product **8c** formed in the catalytic reaction.

Scheme S1





(-)-(R_s)-2-Methyl-*N*-(pent-4-en-1-ylidene)propane-2-sulfinamide (S4). This compound was prepared according to the procedure reported by Ellman.^[4] A flame-dried flask was cooled under a stream of N₂ and charged with pent-4-enal (1.38 mL, 14 mmol) and THF (40 mL). Titanium ethoxide (4.2 mL, 20 mmol) was added and the reaction mixture was stirred at rt for 5 min. (*R*)-*tert*-butanesulfinamide (1.21 g, 10 mmol) was added in one portion and the mixture was stirred overnight (ca. 14 h) at rt. The reaction mixture was poured into brine (40 mL) and stirred for 10 min. Ethyl acetate (20 mL) was added, the mixture was filtered through celite and the celite was washed with ethyl acetate (50 mL). The mixture was transferred to a separatory funnel, brine (20 mL) was added, and the layers were separated. The aqueous phase was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 1.38 g (74%) of the title compound as a colorless oil. Spectroscopic properties are identical to those previously reported.^[5] ¹H NMR (500 MHz, CDCl₃)

δ 8.08 (t, J = 4.5 Hz, 1 H), 5.84 (ddt, J = 4.5, 10.0, 17.0 Hz, 1 H), 5.08 (dd, J = 1.5, 17.0 Hz, 1 H), 5.02 (dd, J = 1.5, 10.0 Hz, 1 H), 2.63 (td, J = 4.0, 7.5 Hz, 2 H), 2.40 (q, J = 7.0 Hz, 2 H), 1.19 (s, 9 H).



(Rs, 4R)-2-Methyl-N-(octa-1,7-dien-4-yl)propane-2-sulfinamide (S5). A flame-dried flask was cooled under a stream of N₂ and charged with freshly ground magnesium turnings (720 mg, 4 equiv). The magnesium was suspended in ether (14.8 mL, 1 M), cooled to 0 °C in an ice/water bath and allyl bromide (1.28 mL, 14.8 mmol) was added dropwise. After addition, the ice bath was removed, and the reaction mixture was stirred at rt for 30 min. Stirring was stopped and the solution was filtered through glass wool prior to addition to S4. A flame-dried flask was cooled under a stream of N₂ and charged with S4 (1.38 g, 7.4 mmol) and THF (37 mL, 0.2 M). The sulfinyl imine solution was cooled to 0 °C in an ice/water bath before the filtered Grignard reagent solution was added dropwise. The reaction mixture was stirred at 0 °C until the starting material had been completely consumed as judged by TLC analysis (1 h). Water was then added dropwise until precipitation of magnesium salts occurred and the resulting solution was decanted into a separate flask. The solution was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. Analysis of the crude product by ¹H NMR indicated that a 10:1 mixture of diastereomers had formed. The crude material was purified by flash chromatography on silica gel to afford 1.02 g (60%) of the title compound as a 10:1 mixture of diastereomers as a clear colorless oil. Data are for the major isomer. ¹H NMR (500 MHz, CDCl₃) d 5.83–5.74 (m, 2 H), 5.18–4.97 (m, 4 H), 3.36–3.32 (m, 1 H), 3.21 (d, J = 6.5 Hz, 1 H), 2.45–2.40 (m, 1 H), 2.37-2.32 (m, 1 H), 2.18-2.08 (m, 2 H), 1.62-1.58 (m, 2 H), 1.21 (s, 9 H).



(*R*)-*tert*-Butyl octa-1,7-dien-4-ylcarbamate (S1). A flame-dried flask was cooled under a stream of N_2 and charged with S5 (1.02 g, 4.4 mmol) and methanol (22 mL). A solution of anhydrous hydrochloric acid (4.4 mL, 17.7 mmol, 4 M in dioxane) was added and the mixture was stirred at rt for 1 h, at which time TLC analysis indicated that the starting material had been

completely consumed. The reaction mixture was diluted with water (10 mL) and CH_2Cl_2 (10 mL), basified with NH₄OH to pH > 12, and transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted with CH_2Cl_2 (3 x 5 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude product was dissolved in THF (44 mL, 0.1 M), solid di-*tert*-butyldicarbonate (1.2 g, 5.3 mmol) was added and the reaction mixture was stirred at rt for 3 h. 1 M NaOH (5 mL) was added and the resulting biphasic mixture was stirred for 1 h at rt. The mixture was transferred to a separatory funnel, the layers were separated and the aqueous layer was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 941 mg (94%) of the title compound as a clear colorless oil. The spectroscopic properties of this compound were identical to that of compound (±)-S1 described above.



(*E*,2*R*,5*S*)-*tert*-Butyl 2-allyl-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxylate (S2). A flamedried Schlenk flask was cooled under a stream of N₂ and charged with $Pd_2(dba)_3$ (77 mg, 0.084 mmol), tri(2-furyl)phosphine (77 mg, 0.33 mmol) and NaO*t*Bu (802 mg, 8.4 mmol). The flask was purged with N₂, then a solution of (*R*)-S1 (941 mg, 4.2 mmol) in freshly distilled xylenes (21 mL) was added via syringe and the resulting mixture was stirred at rt for 2 min. (*E*)-(2bromovinyl)trimethylsilane (1.28 mL, 8.4 mmol) was added and the flask was heated to 140 °C and stirred for 3 h. The mixture was cooled to room temperature and saturated aqueous NH₄CI (10 mL) and ethyl acetate (10 mL) were added. The layers were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (20 mL). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 647 g (48%) of the title compound as a dark brown oil. The spectroscopic properties of this compound were identical to that of compound (±)-S2 described above.



(E,2R,5S)-2-AllyI-N-(4-chlorophenyI)-5-[3-(trimethylsilyI)allyI]pyrrolidine-1-carboxamide (S6). A round-bottom flask equipped with a stirbar was charged with (E,2R,5S)-S2 (647 mg, 2.0 mmol) and dichloromethane (20 mL, 0.1 M). Trifluoroacetic acid (2.0 mL, 1.0 M) was added to the flask and the mixture was stirred for 20 min at rt. The solution was diluted with water, basified with NH₄OH to pH > 12, and transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (3 x 5 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was dissolved in dichloromethane (20 mL, 0.1 M) and 4-chlorophenyl isocyanate (369 mg, 1.2 equiv) was added. The reaction mixture was stirred at rt for 1 h until starting material had been completely consumed as judged by TLC analysis. The crude reaction mixture was concentrated in vacuo, and purified by flash chromatography on silica gel to afford 244 mg (32%) of the title compound as a orange brown oil. ¹H NMR (500 MHz, CDCl₃) δ 7.31 (d, J = 9.0 Hz, 2 H), 7.22 (d, J = 9.0 Hz, 2 H), 6.41 (s, 1 H), 6.04 (dt, J = 7.0, 18.5 Hz, 1 H), 5.93–5.84 (m, 1 H), 5.82 (d, J = 18.5 Hz, 1 H), 5.22–5.17 (m, 2 H), 4.02–3.95 (m, 2 H), 2.61–2.52 (m, 2 H), 2.35 (dt, J = 7.0, 13.5 Hz, 1 H), 2.24 (dt, J = 7.5, 14.0 Hz, 1 H), 2.02–1.96 (m, 2 H), 1.80–1.74 (m, 2 H), 0.05 (s, 9 H).



(E,Z,3R,4aR,7S)-2-(4-Chlorophenyl)-3-(pent-2-en-1-yl)-7-[3-

(trimethylsilyl)allyl]hexahydropyrrolo[1,2-*c*]pyrimidin-1(2*H*)-one (S7). A flame-dried Schlenk tube was cooled under vacuum and charged with $Pd_2(dba)_3$ (3.1 mg, 0.003 mmol), PCy_3HBF_4 (5.0 mg, 0.014 mmol) and NaO*t*Bu (25 mg, 0.26 mmol). The flask was evacuated and purged with N₂. A solution of **S6** (65 mg, 0.17 mmol) in toluene (0.85 mL) was added via syringe and

the resulting mixture was stirred at rt for 2 min. (*Z*)-1-bromobut-1-ene (130 µL, 0.26 mmol, 2.0 M solution in toluene) was added and the tube was heated to 100 °C and stirred until the starting material was completely consumed as judged by TLC analysis (1 h). The mixture was cooled to room temperature and saturated aqueous NH₄Cl (1 mL) and ethyl acetate (1 mL) were added. The layers were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (1 mL). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 53 mg (71%) of the title compound as a yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 7.31 (d, *J* = 9.0 Hz, 2 H), 7.19 (d, *J* = 9.0 Hz, 2 H), 5.94 (ddd, *J* = 6.0, 7.5, 18.5 Hz, 1 H), 5.68 (d, *J* = 18.5 Hz, 1 H), 5.47–5.42 (m, 1 H), 5.12–5.07 (m, 1 H), 4.03 (dt, *J* = 2.5, 8.5 Hz, 1 H), 3.90 (dt, *J* = 4.5, 9.5 Hz, 1 H), 3.66 (ddt, *J* = 2.5, 5.0, 11.5 Hz, 1 H), 2.73 (dd, *J* = 5.5, 12.5 Hz, 1 H), 2.27–2.16 (m, 4 H), 2.01–1.89 (m, 4 H), 1.84–1.81 (m, 1 H), 1.69–1.61 (m, 2 H), 0.90 (t, *J* = 7.5 Hz, 3 H), 0.03 (s, 9 H).



(+)-(*Z*,3*R*,4*aR*,7*S*)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2*c*]pyrimidin-1(2*H*)-one (*ent*-8*c*). A Schlenk tube was charged with **S7** (53 mg, 0.12 mmol) and CH₂Cl₂ (1.2 mL). TFA (0.6 mL) was added and the reaction mixture was stirred overnight at 40 °C. The reaction mixture was then cooled to rt, diluted with water (1 mL), and basified with NH₄OH to pH > 12. The reaction mixture was transferred to a separatory funnel and the layers were separated. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel. This procedure afforded 29 mg (67%) of the title compound as a yellow oil: $[\alpha]^{23}_{D}$ +17.7 (*c* 2.9, CH₂Cl₂). The spectroscopic properties of this compound were identical to that of compound 8*c*. The enantiopurity was determined to be 10:90 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 190 nm, RT= 13.4 and 17.8 min).

References

[1] H. Harada, R. K. Thalji, R. G. Bergman, J. A. Ellman, J. Org. Chem. 2008, 73, 6772–6779.

[2] S. Hanessian, A. Tehim, P. Chen, J. Org. Chem. 1993, 58, 7768–7781.

[3] S. J. Veenstra, P. Schmid, *Tetrahedron Lett.* **1997**, *38*, 997–1000.

[4] G. Liu, D. A. Cogan, T. D. Owens, T. P. Tang, J. A. Ellman, *J. Org. Chem.* **1999**, *64*, 1278–1284.

[5] N. R. Babij, J. P. Wolfe, Angew. Chem. **2012**, *124*, 4204–4206; Angew. Chem. Int. Ed. **2012**, *51*, 4128–4130.






200 180 160 140 120 100 80 60 40 20 0 ppm



Sample Name:					Ag	lent rechnologies
Data Collected on:						
Yb-vnmrs700						
Archive directory:						
Sample directory:						
FidFile: NRB-4-100-A-13	c					
Pulse Sequence: CARBON (s2pul)					
Solvent: cdcl3						
Data collected on: Oct 1	5 2012					
			l			
			1			
	1					
la des a lates a composition de la comp	an sa a dada dhi kima dha ku a sha ka ku ku	nu lakatikuu min anka dahla dha dha dha	tenteri da ta stika da stikiza a seza da tul incenti a suf	der delen der bereiten die stellen bei der bei der	listenska oculistik starovski da svati obraza istova	(sinne kan Atasinata Atatin
a na sa	n a geblenhiði meih fir en min heing	nu (shaji) u taga piratiki ka ipaliya	h salad da i sak karda di Marana ya pada i tu janansida wak A salad da i sak karda di Marana ya pada ya ang pada di karda	nis a della ches tras el color tinta di su aci las das s Appendir a cara a processa di su a cara a companya de seguna	linter en de securétifie de la matérieux contente de la contente de la contente de la contente de la contente e	si senang kuna katen dan dan dika dika dika Naga dan sang katen dan dika dika dika dika dika dika dika dika
			hang ng n			liyan in Mariya diniya TTTTTTTTTTT







Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: NRB-4-135-sm

Pulse Sequence: PROTON (s2pul) Solvent: cdcl3 Data collected on: Dec 21 2012





Sample Name:

Data Collected on: Sn.Chem.LSA.UMich.edu-inova500 Archive directory:

Sample directory:

FidFile: NRB-4-79-sm-13C

Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Sep 12 2012





Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: NRB-4-100-C

Pulse Sequence: PROTON (s2pul) Solvent: cdcl3 Data collected on: Oct 16 2012





Sample Name:

Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: NRB-4-100-C-13C

Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Oct 16 2012



Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory: FidFile: NRB-4-100-D-1H

Pulse Sequence: PROTON (s2pul) Solvent: cdcl3 Data collected on: Oct 16 2012





Sample Name:

Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: NRB-4-100-D-13C

Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Oct 16 2012



Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: NRB-4-100-E-1H

Pulse Sequence: PROTON (s2pul) Solvent: cdcl3 Data collected on: Oct 16 2012









Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: NRB-4-22-X-13C

Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Oct 18 2012



C:\LabSoluti	ons\Data\BABIJ\RACEMIC-NRB-4-11-PMP-Z-BUTENE-100-ADH-2.5%IPA-0.75ml_min.lcd
Acquired by	: Admin –
Sample Name	: RACEMIC-NRB-4-11-PMP-Z-BUTENE-100-ADH-2.5%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-11-PMP-Z-BUTENE-100-ADH-2.5%IPA-0.75ml_min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 10/24/2012 1:59:11 PM
Data Processed	: 10/24/2012 2:54:56 PM

<Chromatogram>



1 PDA Multi 1/245nm 4nm

PeakTable

PDA Ch1 24	5nm 4nm			
Peak#	Ret. Time	Area	Height	Area %
1	44.346	12121126	126849	51.297
2	48.073	11508366	99562	48,703
Total		23629492	226411	100.000



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-11-PMP-Z-BUTENE-100-ADH-2.5%IPA-0.75ml_min.lcd

ABABIJCHIRAL-NRB-4-11-PMP-Z-BUTENE-90-SSIPHOSPE-ADH-2.5%IPA-0.75ml_min.lcd
: Admin
: CHIRAL-NRB-4-11-PMP-Z-BUTENE-90-SSIPHOSP-ADH-2.5%IPA-0.75ml_min
: <sample></sample>
:1
:1
:1uL
: CHIRAL-NRB-4-11-PMP-Z-BUTENE-90-SSIPHOSPE-ADH-2.5%IPA-0.75ml min.lcd
: Cyclic Urea Method.lcm
: Default.lcr
: 5/2/2012 6:06:42 PM
: 5/2/2012 7:02:07 PM

<Chromatogram>



PeakTable

PDA Ch1 245nm 4nm				
Peak#	Ret. Time	Area	Height	Area %
1	44.237	12187752	106584	86.224
2	49.097	1947258	15346	13.776
Total		14135011	121931	100.000



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-11-PMP-Z-BUTENE-90-SSIPHOSPE-ADH-2.5%IPA-0.75ml_min.lcd



Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: NRB-4-101-X-13C



C:\LabSolution:	s/Data/BABIJ/RACEMIC-NRB-4-101-34PMP-Z-BUTENE-100-PCY3-ADH-5%IPA-0.75ml.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-101-3,4PMP-Z-Butene-100C-ADH-5%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-101-34PMP-Z-BUTENE-100-PCY3-ADH-5%IPA-0.75ml.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 10/17/2012 3:45:42 PM
Data Processed	: 10/17/2012 4:18:20 PM

<Chromatogram>



1 PDA Multi 1/205nm 4nm

PeakTable

PDA Ch1 20	Snm 4nm			
Peak#	Ret. Time	Area	Height	Area %
1	21.169	34368966	550494	49.582
2	24.035	34947914	487647	50.418
Total		69316880	1038141	100.000



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-101-34PMP-Z-BUTENE-100-PCY3-ADH-5%IPA-0.75ml.lcd

C:\LabSolutions\Data\	BABIJ/CHIRAL-NRB-4-101-34PMP-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-101-34PMP-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: CHIRAL-NRB-4-101-34PMP-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 10/17/2012 9:55:54 PM
Data Processed	: 10/17/2012 10:28:13 PM

<Chromatogram>



1 PDA Multi 1/205nm 4nm

PeakTable

1A CE1 20	Som Anm				
Peak#	Ret. Time	Area	Height	Area %	Height %
1	20.395	81981175	1343363	81.873	84.618
2	23.463	18150993	244195	18.127	15.382
Total		100132168	1587557	100.000	100.000



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-101-34PMP-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd



Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: NRB-4-95-X-13C

Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Oct 18 2012



Agilent Technologies

C:\LabSolut	ions\Data\BABIJ\RACEMIC-NRB-4-95-pCI-Z-BUTENE-100-PCY3-5%IPA-0.75ml min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-95-pCI-Z-BUTENE-100-PCY3-5%IPA-0.75ml min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-95-pCI-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lod
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 10/10/2012 3:40:20 PM
Data Processed	: 10/10/2012 4:01:04 PM

<Chromatogram>



1 PDA Multi 1/190nm 4nm

PeakTable

PDA Ch1 19	0nm 4nm		reakrable	
Peak#	Ret. Time	Area	Height	Area %
1	13.356	10978832	430437	50.161
2	18.045	10908139	295015	49.839
Total		21886971	725452	100.000



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-95-pCI-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lcd

C:\LabSolutions\Data	\BABIJ\CHIRAL-NRB-4-118-pCI-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-118-pCI-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: CHIRAL-NRB-4-118-pCI-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lor
Data Acquired	: 11/30/2012 12:32:03 PM
Data Processed	: 11/30/2012 1:30:42 PM

<Chromatogram>



1 PDA Multi 1/190nm 4nm

PeakTable PDA Ch1 190nm 4nm Height 1771633 Peak# Ret. Time Area Area % 13.363 40981053 94.402 18.080 2430175 83915 5.598 Total 43411228 100.000 1855548



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-118-pCI-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd

C	:\LabSolutions\Data\BABIJ\ELLMAN-NRB-4-133-2-pCI-Zbutene5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: ELLMAN-NRB-4-133-2-pCI-Zbutene5%IPA-0.75ml_min
Sample ID	: <sample></sample>
frav#	:1
/ail #	:1
njection Volume	: 1 uL
Data File Name	: ELLMAN-NRB-4-133-2-pCI-Zbutene5%IPA-0.75ml_min.lcd
Aethod File Nam	e : Cyclic Urea Method.lcm
Batch File Name	
Report File Name	a : Default.lcr
Data Acquired	: 12/18/2012 11:59:32 AM
Data Processed	: 12/18/2012 12:39:48 PM

<Chromatogram>



1 PDA Multi 1/190nm 4nm

PeakTable

PDA Ch1 190nm 4nm				
Peak#	Ret. Time	Area	Height	Area %
1	13.351	1900239	77384	9.636
2	17.847	17820385	506100	90.364
Total		19720624	583483	100.000



C:\LabSolutions\Data\BABIJ\ELLMAN-NRB-4-133-2-pCI-Zbutene--5%IPA-0.75mI_min.lcd



- Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: NRB-4-103-13C

Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Oct 20 2012



C:\LabSolut	ions\Data\BABIJ\RACEMIC-NRB-4-74-pBr-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-74-pBr-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-74-pBr-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 8/28/2012 6:58:36 PM
Data Processed	: 8/28/2012 7:25:17 PM

<Chromatogram>



1 PDA Multi 1/205nm 4nm

PeakTable

DA (01.1 00	Com Anno	- currenter		
Peak#	Ret. Time	Area	Height	Area %
1	14.517	154799302	3681642	49.793
2	19.163	156088664	2926638	50.207
Total		310887966	6608280	100.000



C:\LabSolutions	Data\BABIJ\CHIURAL-NRB-4-74-pBr-Z-BUTENE-100-SIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIURAL-NRB-4-74-pBr-Z-BUTENE-100-SIPHOSPE-5%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	:1uL
Data File Name	: CHIURAL-NRB-4-74-pBr-Z-BUTENE-100-SIPHOSPE-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 8/28/2012 7:28:02 PM
Data Processed	: 10/19/2012 7:38:06 PM

<Chromatogram>



1 PDA Multi 1/205nm 4nm

DDA Chi aosan A

PeakTable

PDA Ch1 205hm 4hm				
Peak#	Ret. Time	Area	Height	Area %
1	14.528	32443013	1090281	94.464
2	20.017	1901139	49794	5.536
Total		34344152	1140076	100.000



C:\LabSolutions\Data\BABIJ\CHIURAL-NRB-4-74-pBr-Z-BUTENE-100-SIPHOSPE-5%IPA-0.75ml_min.lcd



Agilent Technologies



Sample Name:

Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Oct 18 2012



C:\LabSolution	s\Data\BABIJ\RACEMIC-NRB-4-102-pCN-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-102-pCN-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-102-pCN-Z-BUTENE-100-PCY3-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 10/17/2012 4:27:14 PM
Data Processed	: 10/17/2012 5:22:38 PM

<Chromatogram>



1 PDA Multi 1/205nm 4nm

PeakTable PDA Ch1 205nm 4nm Height 559423 Peak# Ret. Time Area 38677775 Area % 33.091 50.478 41.446 37945343 343252 49.522 2 Total 76623118 902676 100.000 0′′ NA H \dot{C}_2H_5 ĊN

8e

C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-102-pCN-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lcd

ABIJ/CHIRAL-NRB-4-102-2-pCN-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
: Admin
: CHIRAL-NRB-4-102-2-pCN-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75
: <sample></sample>
:1
:1
:1 uL
: CHIRAL-NRB-4-102-2-pCN-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
: Cyclic Urea Method.lcm
: .
: Default.lcr
: 10/23/2012 6:10:26 PM
: 10/23/2012 7:08:32 PM

<Chromatogram>



1 PDA Multi 1/205nm 4nm

PeakTable PDA Ch1 205nm 4nm Ret. Time 33.160 42.857 Height Area % Peak# Area 57259672 3262654 784638 94.609 31536 5.391 Total 60522326 816174 100.000



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-102-2-pCN-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd





C:\LabSolutions\E	Data/BABIJ/RACEMIC-NRB-4-106-2-pNO2-Z-BUTENE-120-SSIPHOSPE-5%IPA-1.5ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-106-2-pNO2-Z-BUTENE-120-SSIPHOSPE-5%IPA-1.5ml
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	:1uL
Data File Name	: RACEMIC-NRB-4-106-2-pNO2-Z-BUTENE-120-SSIPHOSPE-5%IPA-1.5ml min.lcd
Method File Name	: Cvclic Urea Method.lcm
Batch File Name	
Report File Name	Default.lcr
Data Acquired	: 10/30/2012 4:06:25 PM
Data Processed	: 10/30/2012 4:40:18 PM

<Chromatogram>



1 PDA Multi 1/310nm 4nm

PeakTable

DA CE1 31	Onen Anen	reakitable	·	
Peak#	Ret. Time	Area	Height	Area %
1	19.256	10775717	217860	49.820
2	25.832	10853467	168010	50.180
Total		21629184	385871	100.000



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-106-2-pNO2-Z-BUTENE-120-SSIPHOSPE-5%IPA-1.5ml_min.lcd

C:\LabSolutions\Dat	a\BABIJ\CHIRAL-NRB-4-106-pNO2-Z-BUTENE-120-NaOtBu-SSIPHOSPE-5%IPA-1.5ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-106-pNO2-Z-BUTENE-120-NaOtBu-SSIPHOSPE-5%IPA-1.5ml
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: CHIRAL-NRB-4-106-pNO2-Z-BUTENE-120-NaOtBu-SSIPHOSPE-5%IPA-1.5ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	:
Report File Name	: Default.lcr
Data Acquired	: 10/30/2012 2:49:31 PM
Data Processed	: 10/30/2012 3:23:55 PM

<Chromatogram>







C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-106-pNO2-Z-BUTENE-120-NaOtBu-SSIPHOSPE-5%IPA-1.5ml_min.lcd



STANDARD PROTON PARAMETERS

Sample Name:

Data Collected on: Te-vnmrs500 Archive directory:

Sample directory:

FidFile: NRB-4-140-X-13C

Pulse Sequence: CARBON (s2pul) Solvent: cdc13 Data collected on: Jan 6 2013



C:\LabSolutions\l	Data/BABIJ/RACEMIC-NRB-4-140-pCI-Ehexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-140-pCI-Ehexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-140-pCI-Ehexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 1/4/2013 4:14:52 PM
Data Processed	: 1/4/2013 4:58:59 PM

<Chromatogram>



1 PDA Multi 1/205nm 4nm

PeakTable DA Ch1 205nm 4nm				
Peak#	Ret. Time	Area	Height	Area %
1	20.727	13698615	239789	50.749
2	37.695	13294427	136862	49.251
Total		26993042	376651	100.000



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-140-pCI-Ehexene-100-NaOtBu-PCy3-1.5%IPA-1.5mI_min.lcd

C:\LabSolutions\Data	ABABIJ\CHIRAL-NRB-4-140-X-2-pCI-Ehexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-140-X-2-pCI-Ehexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	:1uL
Data File Name	: CHIRAL-NRB-4-140-X-2-pCI-Ehexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5ml_min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	: 1
Report File Name	: Default.lcr
Data Acquired	: 1/4/2013 4:59:58 PM
Data Processed	: 1/4/2013 5:42:12 PM

<Chromatogram>



1 PDA Multi 1/205nm 4nm

PeakTable







Agilent Technologies Sample Name: Data Collected on: Yb-vnmrs700 Archive directory: Sample directory: FidFile: NRB-4-141-X-13C Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Jan 8 2013 0 ppm 180 160 140 120 100 80 60 40 20

C:\LabSolutions\	Data\BABIJ\RACEMIC-NRB-4-141-R-pCI-Zhexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-141-R-pCI-Zhexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_m
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	:1uL
Data File Name	: RACEMIC-NRB-4-141-R-pCI-Zhexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	:
Report File Name	: Default.lcr
Data Acquired	: 1/8/2013 12:32:09 PM
Data Processed	: 1/8/2013 1:30:14 PM

<Chromatogram>



1 PDA Multi 1/254nm 4nm

PeakTable PDA Ch1 254nm 4nm Area 27108175 26082514 53190689 Area % 50.964 49.036 100.000 Height 474557 Peak# Ret. Time 20.055 2 33.734 222410 Total 696967 N 0⁄⁄ Т Н 'N´ \dot{C}_4H_9 CI 8h

C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-141-R-pCI-Zhexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_min.lcd

C:\LabSolutions\Data	\BABIJ\CHIRAL-NRB-4-141-X-pCI-Zhexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-141-X-pCI-Zhexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: CHIRAL-NRB-4-141-X-pCI-Zhexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5ml_min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 1/7/2013 5:02:46 PM
Data Processed	: 1/7/2013 5:47:55 PM

<Chromatogram>



PeakTable

PDA Ch1 254nm 4nm				
Peak#	Ret. Time	Area	Height	Area %
1	20.939	5164727	95174	93.561
2	36.238	355461	4348	6.439
Total		5520188	99522	100.000



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-141-X-pCI-Zhexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5ml_min.lcd



Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: NRB-4-134-X-13C

Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Dec 19 2012



C:\\Data\BABI	J/CHIRAL-NRB-4-123-pCI-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-123-pCI-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	:1uL
Data File Name	: CHIRAL-NRB-4-123-pCI-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 12/11/2012 6:02:30 PM
Data Processed	: 12/11/2012 6:43:19 PM

<Chromatogram>



1 PDA Multi 1/254nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	14.325	16086664	615989	50.923
2	23.320	15503816	317951	49.077
Total		31590479	933941	100.000



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-123-pCI-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd

C:\\Data\BABIJ	CHIRAL-NRB-4-134-X-pCI-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-134-X-pCI-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	:1uL
Data File Name	: CHIRAL-NRB-4-134-X-pCI-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lod
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 12/19/2012 3:20:33 PM
Data Processed	: 12/19/2012 3:51:53 PM

<Chromatogram>



1 PDA Multi 1/254nm 4nm

PeakTable

PDA Ch1 25	PDA Ch1 254nm 4nm					
Peak#	Ret. Time	Area	Height	Area %		
1	13.819	40943767	1527198	93.771		
2	23.975	2719612	58406	6.229		
Total		43663379	1585604	100.000		



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-134-X-pCI-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd



180 160 140 120 100 80 60 40 20 ppm
C:\LabSolutio	ns\Data\BABIJ\RACEMIC-NRB-4-126-2-pCI-2Propene-100-PCY3-3%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-126-2-pCI-2Propene-100-PCY3-3%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-126-2-pCI-2Propene-100-PCY3-3%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 12/20/2012 1:52:01 PM
Data Processed	: 12/20/2012 2:31:47 PM

<Chromatogram>





DDA Ch1 254cm 4cm

PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	23.235	26432880	621250	49.297
2	28.496	27186656	434267	50,703
Total		53619536	1055517	100.000



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-126-2-pCI-2Propene-100-PCY3-3%IPA-0.75ml_min.lcd

BABIJ/CHIRAL-NRB-4-135-2-pCI-2propene-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml_min.lcd
: Admin
: CHIRAL-NRB-4-135-2-pCI-2prop-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml
: <sample></sample>
:1
:1
:1uL
: CHIRAL-NRB-4-135-2-pCI-2propene-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml_min.lcd
: Cyclic Urea Method.lcm
: Default.lcr
: 12/20/2012 5:22:09 PM
: 12/20/2012 6:22:39 PM

<Chromatogram>



1 PDA Multi 1/254nm 4nm

PeakTable

DA Ch1 25	h1 254nm 4nm				
Peak#	Ret. Time	Area	Height	Area %	
1	22.761	6535743	152637	88.459	
2	28.377	852687	14946	11.541	
Total		7388431	167583	100.000	



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-135-2-pCI-2propene-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml_min.lcd







C:\LabSolu	itions\Data\BABIJ\RACEMIC-NRB-4-55-pCI-TOLYL-100-PCY3-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-55-pCI-TOLYL-100-PCY3-5%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-55-pCI-TOLYL-100-PCY3-5%IPA-0.75ml_min.lod
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 8/8/2012 2:44:19 PM
Data Processed	: 8/8/2012 3:10:15 PM

<Chromatogram>



PeakTable

PDA Ch1 25	4nm 4nm			
Peak#	Ret. Time	Area	Height	Area %
1	16.956	44268953	1299090	50.371
2	18.366	43617224	974723	49.629
Total		87886176	2273813	100.000



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-55-pCI-TOLYL-100-PCY3-5%IPA-0.75ml_min.lcd

C:\LabSolutions\Da	ta\BABIJ\CHIRAL-NRB-4-92-2-pCI-4-TOLYL-100-NAOtBU-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-92-2-pCI-TOLYL-100-NAOtBU-SSIPHOSPE-5%IPA-0.75ml_m
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: CHIRAL-NRB-4-92-2-pCI-4-TOLYL-100-NAOtBU-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 9/28/2012 4:49:24 PM
Data Processed	: 9/28/2012 5:13:28 PM

<Chromatogram>



1 PDA Multi 1/254nm 4nm

PDA Ch1 254pm 4pm

PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	17.335	16104566	506093	92.981
2	19.436	1215674	32944	7.019
Total		17320240	539037	100.000



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-92-2-pCl-4-TOLYL-100-NAOtBU-SSIPHOSPE-5%IPA-0.75ml_min.lcd



Sample Name:

Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: CARBON

Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Oct 25 2012



Agilent Technologies

C:\LabS	olutions\Data\BABIJ\RACEMIC-NRB-4-86-pCI-OMe-100-PCY3-3%IPA-0.75ml min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-86-pCI-OMe-100-PCY3-3%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-86-pCI-OMe-100-PCY3-3%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 11/29/2012 6:05:51 PM
Data Processed	: 11/29/2012 7:24:45 PM

<Chromatogram>



1 PDA Multi 1/204nm 4nm

PeakTable

DA Ch1 20	A Ch1 204nm 4nm				
Peak#	Ret. Time	Area	Height	Area %	
1	48.326	123683130	1316190	50.164	
2	52.485	122874255	830445	49.836	
Total		246557385	2146635	100.000	



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-86-pCI-OMe-100-PCY3-3%IPA-0.75ml_min.lcd

\BABIJ\CHIRAL-NRB-4-116-pCI-4-OMe-21-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml_min.lcd
: Admin
: CHIRAL-NRB-4-116-pCI-4-OMe-21-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml
: <sample></sample>
:1
:1
: 1 uL
: CHIRAL-NRB-4-116-pCI-4-OMe-21-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml min.lcd
: Cyclic Urea Method.lcm
: Default.lcr
: 11/29/2012 4:44:16 PM
: 11/29/2012 6:04:21 PM

<Chromatogram>



1 PDA Multi 1/204nm 4nm

PeakTable

DA Ch1 204nm 4nm					
Peak#	Ret. Time	Area	Height	Area %	
1	49.292	41066585	412959	92.385	
2	55.654	3384865	26148	7.615	
Total		44451450	439107	100.000	



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-116-pCl-4-OMe-21-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml_min.lcd



k Agilen Technologies
keeping Hame:
kee

180 160 140 120 100 80 60 40 20 ppm

C:\LabSolut	ions\Data\BABIJ\RACEMIC-NRB-4-96-pCI-PHENYL-100-PCY3-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-96-pCI-PHENYL-100-PCY3-5%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-96-pCI-PHENYL-100-PCY3-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 10/10/2012 2:52:59 PM
Data Processed	: 10/10/2012 3:24:59 PM

<Chromatogram>



1 PDA Multi 1/245nm 4nm

PeakTable

PDA Ch1 24	Snm 4nm	reakrabie		
Peak#	Ret. Time	Area	Height	Area %
1	21.348	6370242	157244	50.083
2	24.417	6349172	118480	49.917
Total		12719414	275724	100.000



C:\LabSolutions\Da	hta\BABIJ\CHIRAL-NRB-4-96-pCI-PHENYL-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	Admin
Sample Name	: CHIRAL-NRB-4-96-pCI-PHENYL-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_mi
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: CHIRAL-NRB-4-96-pCI-PHENYL-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 10/10/2012 3:37:24 PM
Data Processed	: 10/10/2012 4:11:56 PM

<Chromatogram>



1 PDA Multi 1/245nm 4nm

 PeakTable

 PDA Ch1 245nm 4nm
 Area
 Height
 Area %

 1
 21.087
 32587442
 843023
 90.230

 2
 24.216
 3528682
 67790
 9.770

 Total
 36116124
 910813
 100.000



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-96-pCI-PHENYL-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd





C:\LabSol	utions\Data\BABIJ\RACEMIC-NRB-4-58-pCI-CF3-100-PCY3-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-58-pCI-CF3-100-PCY3-5%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-58-pCI-CF3-100-PCY3-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 8/10/2012 1:42:35 PM
Data Processed	: 8/10/2012 2:12:09 PM

<Chromatogram>



PeakTable

PDA Ch1 20	2DA Ch1 205nm 4nm				
Peak#	Ret. Time	Area	Height	Area %	
1	19.836	31756926	766828	49.635	
2	26.478	32223518	510700	50.365	
Total		63980444	1277528	100.000	



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-58-pCI-CF3-100-PCY3-5%IPA-0.75ml_min.lcd

C:\LabSolutions\E	Data\BABIJ\CHIRAL-NRB-4-107-pCI-4-CF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-107-pCI-4-CF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_m
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: CHIRAL-NRB-4-107-pCI-4-CF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 11/1/2012 1:56:29 PM
Data Processed	: 11/1/2012 2:29:27 PM

<Chromatogram>



1 PDA Multi 1/205nm 4nm

PeakTable

PDA Ch1 205nm 4nm				
Peak#	Ret. Time	Area	Height	Area %
1	19.852	55981453	1343838	84.851
2	27.472	9994947	167907	15.149
Total		65976400	1511745	100.000



8n (with NaOtBu)

C:\LabSolution	s\Data\BABIJ\CHIRAL-NRB-4-83-pCI-CF3-95-NAOME-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-83-pCI-CF3-95-NAOME-SSIPHOSPE-5%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: CHIRAL-NRB-4-83-pCI-CF3-95-NAOME-SSIPHOSPE-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	:
Report File Name	: Default.lcr
Data Acquired	: 9/13/2012 7:30:51 PM
Data Processed	: 9/13/2012 8:02:40 PM

<Chromatogram>



1 PDA Multi 1/205nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	19.403	71981301	1731362	90.036
2	26.668	7966346	131922	9.964
Total		79947647	1863284	100.000



8n (with NaOMe)

C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-83-pCI-CF3-95-NAOME-SSIPHOSPE-5%IPA-0.75ml_min.lcd



pCI-OCF3-100-PCY3-5%IPA-0.75ml_min.lcd
PCY3-5%IPA-0.75ml_min
-
PCY3-5%IPA-0.75ml_min.lcd
_

<Chromatogram>



PeakTable

PDA Ch1 24	PDA Ch1 245nm 4nm				
Peak#	Ret. Time	Area	Height	Area %	
1	16.766	13936711	401672	50.472	
2	19.105	13675829	298353	49.528	
Total		27612540	700025	100.000	



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-58-pCI-OCF3-100-PCY3-5%IPA-0.75ml_min.lcd

C:\LabSolutions\	Data\BABIJ\CHIRAL-NRB-4-94-pCI-4-OCF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-94-pCI-4-OCF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_mi
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: CHIRAL-NRB-4-94-pCI-4-OCF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 10/4/2012 10:46:14 AM
Data Processed	: 10/4/2012 11:09:47 AM

<Chromatogram>



1 PDA Multi 1/245nm 4nm

PeakTable

DA Ch1 24	Som dom			
Peak#	Ret. Time	Area	Height	Area %
1	17.124	74360169	1711279	87.935
2	19.768	10202360	209358	12.065
Total		84562529	1920637	100.000



80 (with NaOtBu)

C:\LabSolutions\I	Data/BABIJ/CHIRAL-NRB-4-137-II-pCI-OCF3-100-NaOMe-SSIPHOSPE-5%IPA-0.75ml min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-137-I-pCI-OCF3-100-NaOMe-SSIPHOSPE-5%IPA-0.75ml_mi
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	:1uL
Data File Name	: CHIRAL-NRB-4-137-II-pCI-OCF3-100-NaOMe-SSIPHOSPE-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 12/23/2012 5:45:35 PM
Data Processed	: 12/23/2012 6:13:19 PM

<Chromatogram>



1 PDA Multi 1/245nm 4nm

PeakTable

PDA Ch1 245nm 4nm				
Peak#	Ret. Time	Area	Height	Area %
1	16.764	31880825	954387	92.755
2	19.756	2490104	57122	7.245
Total		34370929	1011509	100.000



80 (with NaOMe)

C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-137-II-pCI-OCF3-100-NaOMe-SSIPHOSPE-5%IPA-0.75ml_min.lcd



C:\LabSol	utions\Data\BABIJ\RACEMIC-NRB-4-90-pCI-3-OMe-100-PCY3-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-90-pCI-3-OMe-100-PCY3-5%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	:1uL
Data File Name	: RACEMIC-NRB-4-90-pCI-3-OMe-100-PCY3-5%IPA-0.75ml_min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 9/25/2012 7:29:03 PM
Data Processed	: 9/25/2012 8:05:08 PM

<Chromatogram>



PeakTable

Peak Table				
Peak#	Ret. Time	Area	Height	Area %
1	27.381	48187230	552654	49.026
2	30.736	50102213	843446	50.974
Total		98289443	1396100	100.000



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-90-pCI-3-OMe-100-PCY3-5%IPA-0.75ml_min.lcd

C:\LabSolutions\D	ata\BABIJ\CHIRAL-NRB-4-94-pCI-3-OMe-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-94-pCI-3-OMe-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml
Sample ID	: <sample></sample>
Trav#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: CHIRAL-NRB-4-94-pCI-3-OMe-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml min.lcd
Method File Name	: Cvclic Urea Method.lcm
Batch File Name	
Report File Name	Default.lcr
Data Acquired	: 10/4/2012 3:33:10 PM
Data Processed	10/4/2012 4:08:43 PM

<Chromatogram>



1 PDA Multi 1/248nm 4nm

PeakTable

		reakitable		
PDA Ch1 24	8nm 4nm			
Peak#	Ret. Time	Area	Height	Area %
1	27.173	5497076	67634	12.683
2	30.594	37845830	483921	87.317
Total		43342907	551556	100.000







C:\LabSolu	tions\Data\BABIJ\RACEMIC-NRB-4-90-pCI-2-napthyl-100-PCY3-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-90-pCI-2-napthyl-100-PCY3-5%IPA-0.75ml_min.lcd
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-90-pCI-2-napthyl-100-PCY3-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 9/26/2012 1:51:54 PM
Data Processed	: 9/26/2012 2:25:28 PM

<Chromatogram>



1 PDA Multi 1/215nm 4nm

PeakTable

PDA Ch1 21	Snm 4nm	r cak raute	·	
Peak#	Ret. Time	Area	Height	Area %
1	24.856	45755831	941390	49.764
2	28.662	46190576	639545	50.236
Total		91946407	1580935	100.000



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-90-pCI-2-napthyl-100-PCY3-5%IPA-0.75ml_min.lcd

C:\LabSolutions\Dat	a\BABIJ\CHIRAL-NRB-4-107-2-pCI-2-napthyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-107-2-pCl-2-napth-100-SSIPHOSPE-5%IPA-0.75ml
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: CHIRAL-NRB-4-107-2-pCI-2-napthyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lod
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 10/31/2012 5:21:45 PM
Data Processed	: 10/31/2012 6:05:47 PM

<Chromatogram>



1 PDA Multi 1/215nm 4nm

PeakTable

PDA Ch1 21	5nm 4nm			
Peak#	Ret. Time	Area	Height	Area %
1	24.372	129657052	2544179	87.682
2	28.231	18215094	271035	12.318
Total		147872146	2815214	100.000



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-107-2-pCI-2-napthyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd





C:\LabSolu	tions\Data\BABIJ\RACEMIC-NRB-4-90-pCI-2-tolyl-100-PCY3-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: RACEMIC-NRB-4-90-pCl-2-tolyl-100-PCY3-5%IPA-0.75ml_min
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	: 1 uL
Data File Name	: RACEMIC-NRB-4-90-pCI-2-tolyl-100-PCY3-5%IPA-0.75ml_min.lcd
Method File Name	: Cyclic Urea Method.lom
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 9/26/2012 11:30:07 AM
Data Processed	: 9/26/2012 12:10:21 PM

<Chromatogram>



1 PDA Multi 1/215nm 4nm

PeakTable

PDA Ch1 21	A Ch1 215nm 4nm				
Peak#	Ret. Time	Area	Height	Area %	
1	19.869	39671328	972024	49.912	
2	23.795	39810829	618614	50.088	
Total		79482157	1590638	100.000	



C:\LabSolutions\Data\BABIJ\RACEMIC-NRB-4-90-pCl-2-tolyl-100-PCY3-5%IPA-0.75ml_min.lcd

C:\LabSolutions\Da	ta\BABIJ\CHIRAL-NRB-4-107-pCI-2-tolyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
Acquired by	: Admin
Sample Name	: CHIRAL-NRB-4-107-pCI-2-tolyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml
Sample ID	: <sample></sample>
Tray#	:1
Vail #	:1
Injection Volume	:1uL
Data File Name	: CHIRAL-NRB-4-107-pCI-2-tolyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml min.lcd
Method File Name	: Cyclic Urea Method.lcm
Batch File Name	
Report File Name	: Default.lcr
Data Acquired	: 10/31/2012 3:36:37 PM
Data Processed	: 10/31/2012 4:33:50 PM

<Chromatogram>



1 PDA Multi 1/215nm 4nm

PeakTable

PDA Chi 215nm 4nm						
Peak#	Ret. Time	Area	Height	Area %		
1	20.144	12340532	334865	70.853		
2	24.282	5076517	94929	29.147		
Total		17417049	429794	100.000		



C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-107-pCI-2-tolyI-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd



Sample Name:

Data Collected on: Sn.Chem.LSA.UMich.edu-inova500 Archive directory:

Sample directory:

FidFile: NRB-4-122-1H

Pulse Sequence: PROTON (s2pul) Solvent: cdcl3 Data collected on: Dec 13 2012









Agilent Technologies

Sample Name:

Data Collected on: Yb-vnmrs700 Archive directory:

Sample directory:

FidFile: NRB-4-100-13C

Pulse Sequence: CARBON (s2pul) Solvent: cdcl3 Data collected on: Oct 23 2012
















иние произдание на и произдание произдание при произдание произ 180 160 140 120 100 80 60 40 20 ppm



F2 (ppm)